US10280229B2 - Linkers and their application towards ADC - Google Patents

Linkers and their application towards ADC Download PDF

Info

Publication number
US10280229B2
US10280229B2 US15/326,386 US201515326386A US10280229B2 US 10280229 B2 US10280229 B2 US 10280229B2 US 201515326386 A US201515326386 A US 201515326386A US 10280229 B2 US10280229 B2 US 10280229B2
Authority
US
United States
Prior art keywords
group
linker
drug
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/326,386
Other versions
US20170202974A1 (en
Inventor
Chun Sing Li
Jian Li
Yong Cang
Shuhui Chen
Gang Li
Xiongbin XU
Lun Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Assigned to MEDSHINE DISCOVERY INC. reassignment MEDSHINE DISCOVERY INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CANG, YONG, CHEN, SHUHUI, LI, CHUN SING, LI, GANG, LI, JIAN, LU, Lun, XU, Xiongbin
Publication of US20170202974A1 publication Critical patent/US20170202974A1/en
Application granted granted Critical
Publication of US10280229B2 publication Critical patent/US10280229B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

  • the present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies.
  • the present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.
  • ADCs Antibody drug conjugates hold the promise as a target specific and effective treatment for a number of diseases e.g. bacterial infection and cancers, but at the same time with an improved systemic side effect profile.
  • the concept to combine a target specific antibody with a cytotoxic compound is very simple and elegant.
  • An antibody is well known for its ability to recognize an antigen in specific manner and the often insufficient cell killing activity following an immune response, limited its therapeutic potential.
  • cyctotoxic compounds are widely used in the treatment of cancers and their effectiveness are hindered by non-specific systemic adverse events associated with higher dose usage.
  • the combination of an antibody with a cyctoxic compound can therefore lead to a therapeutic agent with enhancing efficacy to the antibody and reduced systemic side effects to the cytotoxic drug, attributing to the target specific delivery by the antibody and minimize of normal tissues from drug exposures.
  • linker such as the one in Adcertris, which incorporates a lysosomal enzymatic cleavable peptide component.
  • the C-terminal amide bond in this part of the linker that can be easily cleaved at target cells by lysosomal enzymes is essential to the drug releasing mechanism.
  • Other amide bonds on the linker if undergo prematurely cleavage may lead to undesirable side effects (Formular B-1).
  • This application describes the replacement of the N-terminal amide bond of the lysosomal enzymatic cleavable peptide with an amide surrogate (Formullar B-2). This modification can further improved stability of the resulting ADCs in circulation.
  • the present invention provides a linker of formula (I) to connect drugs to antibodies
  • s 0, 1, 2, 3, or 4;
  • the present invention also provides a drug-linker conjugate of formula (II),
  • the present invention also provides an ADC of formula (III),
  • a is 1, 2, 3, 3.4, 3.5, 4, 4.2, 5, 6, 7, or 8.
  • the aforesaid antibody is selected from the group consisting of a resurfaced monoclonal antibody, a resurfaced single chain monoclonal antibody, or a resurfaced monoclonal antibody fragment that preferentially binds to a target cell.
  • the aforesaid antibody is selected from the group consisting of a humanized monoclonal antibody, a humanized single chain monoclonal antibody, or a humanized monoclonal antibody fragment.
  • the aforesaid antibody is selected from the group consisting of a chimeric antibody, a chimeric antibody fragment, a domain antibody, or a domain antibody fragment thereof.
  • the aforesaid antibody is selected from the group consisting of MY9, anti-B4, EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFR, EGFRvIII, HER2, HER3, mesothelin, cripto, alpha v beta 3 , alpha v beta 5 , alpha v beta 6 integrin or C242.
  • the aforesaid antibody is selected from the group consisting of My9-6, B4, C242, N901, DS6, EphA2 receptor, CD38, IGF-IR, CNTO 95, B-B4, Trastuzumab, Tertuzumab, Bevatuzumab, Sibrotuzumab, Rituximab, and Adalimumab.
  • the aforesaid antibody is selected from the group consisting of Herceptin and Erbitux.
  • the aforesaid antibody binds to target cells selected from tumor cells; virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing one or more of IGF-IR, CanAg, EGFR, MUCI, MUCI 6, VEGF, TF, MY9, anti-B4, EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD11a, CD18, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD70, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFRvIII, HER2/neu, HER3, mesothelin, cripto, alpha v beta 3 integrin, alpha v beta 5 integrin, alpha v beta 6 integrin
  • the aforesaid tumor cells are selected from breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, and testicular cancer cells.
  • the aforesaid drug is a cytotoxic drug.
  • the aforesaid drug is selected from the group consisting of maytansinoid, DNA-binding drug and its analog, calicheamicin, doxorubicin and its analog, vinca alkaloid, cryptophycin, dolastatin, auristatin and analog thereof, tubulysin, epothilone, taxoid and siRNA.
  • the aforesaid DNA-binding drug is CC-1065.
  • the aforesaid M is selected from the group consisting of:
  • the aforesaid drug is a diagnostic or detection reagen.
  • the aforesaid drug is a radio-labeled compound.
  • the aforesaid drug is labeled with 3 H, 18 F, 11 C, 13 N, 15 O, 201 Tl, 32 P, 51 Cr, 67 Ga, 123 I, 125 I, 131 I, 132 I, 131 Cs, 113 Xe, 133 Xe, 169 Yb, 198 Au, 203 Hg, 99m Tc, 113m In, 133m In, 75 Se, 186 Re, 153 Sm, and 89 Sr.
  • the aforesaid L 1 is selected from the group consisting of:
  • the aforesaid L 2 is selected from the group consisting of:
  • the aforesaid L 2 is selected from the group consisting of:
  • the aforesaid ring formed by two geminal R 11 or two adjacent R 11 is cyclohexyl.
  • the aforesaid L 3 is selected from the group consisting of:
  • the aforesaid linker is selected from the group consisting of:
  • the aforesaid linker is selected from the group consisting of:
  • the aforesaid conjugate is selected from the group consisting of:
  • the aforesaid conjugate is selected from the group consisting of:
  • the aforesaid ADC is selected from the group consisting of:
  • Y is an antibody, a is an integer or decimal selected from 1-8, concretely a is 1, 2, 3, 3.4, 3.5, 4, 4.2, 5, 6, 7, or 8.
  • the aforesaid ADC is selected from the group consisting of:
  • Y is an antibody, a is an integer or decimal selected from 1-8, concretely a is 1, 2, 3, 3.4, 3.5, 4, 4.2, 5, 6, 7, or 8.
  • the aforesaid ADC is selected from the group consisting of:
  • a is an integer or decimal selected from 2-6, concretely a is 2, 3, 3.4, 3.5, 4, 4.2, 5, or 6.
  • the aforesaid ADC is selected from the group consisting of:
  • a is an integer or decimal selected from 2-6, concretely a is 2, 3, 3.4, 3.5, 4, 4.2, 5, or 6.
  • the present invention also provides intermediate compound for the synthesis of the drug-linker conjugate of formula (II) or the ADC of formula (III), comprising:
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of the aforesaid ADC and a pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention also provides a use of the aforesaid linker, conjugate, or ADC or the aforesaid composition in the preparation of a medicament for the treatment of cancers.
  • the present invention also provides a method for treating or diagnosising cancers, comprising administrating the subject in need thereof an effective amount of the aforesaid ADC or the aforesaid pharmaceutical composition.
  • C 1-6 is selected from the group consisting of C 1 , C 2 , C 3 , C 4 , C 5 , and C 6 , the number denotes numbers of carbon atoms;
  • C 3-6 is selected from the group consisting of C 3 , C 4 , C 5 , and C 6 .
  • C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cyclohydrocarbyl, C 3-6 heterocyclohydrocarbyl, C 1-6 alkyl substituted by C 3-6 cyclohydrocarbyl or C 3-6 heterocyclohydrocarbyl, and C 1-6 heteroalkyl substituted by C 3-6 cyclohydrocarbyl or C 3-6 heterocyclohydrocarbyl include, but are not limited to: methyl, ethyl, n-propyl, isopropyl, —CH 2 C(CH 3 )(CH 3 )(OH), cyclopropyl, cyclobutyl, propylmethylene, cycropropylacyl, benzyloxyl, cyclopropylalkylene, trifluoromethyl, aminomethyl, hydroxylmethyl, methyloxyl, methylacyl, methyloxylcarbonyl, methylsulfonyl, methylsulfinyl, eth
  • N(CH 3 ) 2 NH(CH 3 ), —CH 2 CF 3 , —CH2CH 2 CF 3 , —CH 2 CH 2 F, —CH 2 CH 2 S( ⁇ O) 2 CH 3 , —CH 2 CH 2 CN,
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, including deuterium “D” atom, a variant of hydrogen, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • a substituent is keto (i.e., ⁇ O)
  • 2 hydrogens on the atom are replaced.
  • Keto substituents are not present on aromatic moieties.
  • optionally substituted means that the designated atom can be substituted or unsubstituted by the substituents, and unless otherwise stated, the species and number the substituents are not defined provided that they can be achieved in Chemistry.
  • any variable e.g., R
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • R e.g., R
  • said group may optionally be substituted with up to two R groups and R at each occurrence is selected independently from the definition of R.
  • substituents and/or variables are permissible only if such combinations result in stable compounds.
  • alkyl and heteroalkyl radicals are generically referred to as “alkyl group substituents,” and they can be one or more of a variety of groups selected from, but not limited to: —R′, —OR′, ⁇ O, ⁇ NR′, ⁇ N—OR′, —NR′R′′,
  • R′, R′′, R′′′, R′′′′ and R′′′′′ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
  • each of the R groups is independently selected as are each R′, R′′, R′′′, R′′′′ and R′′′′′ groups when more than one of these groups is present.
  • R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • —NR′R′′ is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF 3 and —CH 2 CF 3 ) and acyl (e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like).
  • haloalkyl e.g., —CF 3 and —CH 2 CF 3
  • acyl e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like.
  • substituents for the aryl and heteroaryl groups are generically referred to as “aryl group substituents.”
  • the substituents are selected from, for example: —R′, —OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, OC(O)R′, —C(O)R′, —CO2R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, NR′ C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NR′′′′′—C(NR′R′′R′′′) ⁇ NR′′′′, NR′′′′ C(NR′R′′) ⁇ NR′′′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R′′, NR′′SO 2 R′, —CN, —CN, —
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)—(CRR′)q-U—, wherein T and U are independently —NR—, —O—, —CRR′— or a single bond, and q is an integer of from 0 to 3.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A(CH 2 )r B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, S(O) 2 —, —S(O) 2 NR′— or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′)s-X—(CR′′R′′′)d-, where s and d are independently integers of from 0 to 3, and X is —O—, —NR′—, —S—, —S(O)—, —S(O) 2 —, or —S(O) 2 NR′—.
  • the substituents R, R′, R′′ and R′′′ are preferably independently selected from hydrogen or substituted or unsubstituted (C1-C6)alkyl.
  • halo or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl.
  • halo(C1-C4)alkyl is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • haloalkyl examples include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
  • Alkoxy represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • C1-6 alkoxy is intended to include C1, C2, C3, C4, C5, and C6 alkoxy groups.
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy.
  • Cycloalkyl is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. 3-7 cycloalkyl is intended to include C3, C4, C5, C6, and C7 cycloalkyl groups.
  • Alkenyl is intended to include hydrocarbon chains of either straight or branched configuration and one or more unsaturated carbon-carbon bonds that may occur in any stable point along the chain, such as ethenyl and propenyl.
  • Halo or “halogen” as used herein refers to fluoro, chloro, bromo, and iodo.
  • hetero mean, unless otherwise stated, “heteroatom” or “heteroradical”(namely radical containing heteroatom), includeing atoms other than carbon (C) and hydrogen (H), also including the radicals containing these aforesaid heteroatoms. Examples include oxygen (O), nitrogen (N) sulfur (S), silicon (Si), germanium (Ge), aluminum (Al) and boron (B), also include optionally substituted —C( ⁇ O)N(H)—, —N(H)—, —C( ⁇ NH)—, —S( ⁇ O) 2 N(H)—, or —S( ⁇ O) N(H)—.
  • Ring as used herein, means a substituted or unsubstituted cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, heterocycloalkynyl, aryl, or heteroaryl.
  • a ring includes mono, bi, sprio, fused, and bridged ring moieties.
  • the number of atoms in a ring is typically defined by the number of members in the ring.
  • a “5- to 7-membered ring” means there are 5 to 7 atoms in the encircling arrangement. Unless otherwise specified, the ring optionally includes one to three heteroatoms.
  • the term “5- to 7-membered ring” includes, for example phenyl, pyridinyl and piperidinyl.
  • the term “ring” further includes a ring system comprising more than one “ring”, wherein each “ring” is independently defined as above.
  • heterocycle or “heterocyclic group” is intended to mean a stable monocyclic, bicyclic, or tricyclic ring containing heteroatom or heteroradical, which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1,2, 3, or 4 ring heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., NO and S (O) p).
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined).
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • the heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
  • aromatic heterocyclic group or“heteroaryl” is intended to mean a stable 5,6, or 7-membered monocyclic or bicyclic or 7,8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1,2, 3, or 4 heterotams independently selected from the group consisting of N, O and S.
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined).
  • the nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., NO and S (O) p). It is to be noted that total number of S and 0 atoms in the aromatic heterocycle is not more than 1.
  • Bridged rings are also included in the definition of heterocycle.
  • a bridged ring occurs when one or more atoms (i.e., C, O, N, or S) link two non-adjacent carbon or nitrogen atoms.
  • Preferred bridges include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a trycyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
  • heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1, 5,2-dithiazinyl, dihydrofuro [2, 3-b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolen
  • hydrocarbyl or its lower concept(such as alkyl, alkenyl, alkynyl and phenyl etc.) by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. C 1 -C 10 means one to ten carbons).
  • “Hydrocarbyl” include, but are not limited to, aliphatic hydrocarbyl and aromatic hydrocarbyl, and the aliphatic hydrocarbyl include linear and cyclic ones, specifically including but not limited to, alkyl, alkenyl, and alkynyl, and the aromatic hydrocarbyl include, but are not limited to, 6-12 membered aromatichydrocarbyl, for example, benzene, and naphthalene.
  • the term “alkyl” means a straight or branched chain, or combinations thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals.
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • heterohydrocarbyl or its lower concept (such as heteroalkyl, heteroalkenyl, teteroalkynyl and heteroaryl etc.) by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom.
  • heteroalkyl by itself or in combination with another term, means a stable straight or branched chain, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom.
  • the heteroatoms can be selected from the group consisting of B, O, N and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) B, O, N and S may be placed at any interior position of the heterohydrocarbyl group(including the position at which the hydrocarbyl group is attached to the remainder of the molecule).
  • Examples include, but are not limited to, —CH2-CH2-O—CH3, —CH2-CH2-NH—CH3, —CH2-CH2-N(CH3)-CH3, —CH2-S—CH2-CH3, —CH2-CH2,—S(O)—CH3, —CH2-CH2-S(O)2-CH3, —CH ⁇ CH—O—CH3, —CH2-CH ⁇ N—OCH3, and —CH ⁇ CH—N(CH3)-CH3.
  • Up to two heteroatoms may be consecutive, such as, for example, —CH 2 —NH—OCH 3 .
  • alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
  • cyclohydrocarbyl “heterocyclohydrocarbyl”, or their lower concepts(such as aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, and heterocycloalkynyl etc.) by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “hydrocarbyl” or “heterohydrocarbyl”, respectively.
  • a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
  • cycloalkyl examples include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl moieties include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl.
  • aryl means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently.
  • heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms.
  • the heteroatom is selected from B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
  • a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinoly
  • aryl when used in combination with other terms (e.g., aryloxy, arylthio, arylalkyl) includes both aryl and heteroaryl rings as defined above.
  • arylalkyl is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like).
  • alkyl group e.g., benzyl, phenethyl, pyridylmethyl and the like
  • an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naph
  • leaving group means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction.
  • representative leaving groups include triflate, chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
  • protecting group includes bu not limited to “amino-protecting group”, “hydroxy-protecting group” and “thiol-protecting group”.
  • amino-protecting group means a protecting group suitable for preventing undesired reactions at an amino nitrogen.
  • Representative amino-protecting groups include, but are not limited to, formyl; acyl groups, for example alkanoyl groups, such as acetyl, trichloroacetyl or trifluoroacetyl; alkoxycarbonyl groups, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl groups, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups, such as benzyl (Bn), trityl (Tr), and 1,1-di-(4′-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); and the like.
  • alkoxycarbonyl groups such as tert-butoxycarbonyl (Boc)
  • arylmethoxycarbonyl groups such as benzy
  • hydroxy-protecting group means a protecting group suitable for preventing undesired reactions at a hydroxy group.
  • Representative hydroxy-protecting groups include, but are not limited to, alkyl groups, such as methyl, ethyl, and tert-butyl; acyl groups, for example alkanoyl groups, such as acetyl; arylmethyl groups, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), and diphenylmethyl (benzhydryl, DPM); silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); and the like.
  • alkyl groups such as methyl, ethyl, and tert-butyl
  • acyl groups for example alkanoyl groups, such as acetyl
  • arylmethyl groups such as benzyl (Bn), p-meth
  • the “antibody” is a cell-binding agent, it binds to an antigen that is a polypeptide and may be a transmembrane molecule (e.g. receptor) or a ligand such as a growth factor.
  • antigens include molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor vmc, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP
  • CD proteins such as CD2, CD3, CD4, CD5, CD6, CD8, CD11, CD14, CD18, CD19, CD20, CD21, CD22, CD 25, CD26, CD27, CD28, CD30, CD33, CD36, CD37, CD38, CD40, CD44, CD52, CD55, CD56, CD70, CD79, CD80, CD81, CD103, CD105, CD134, CD137, CD138, and CD152; members of the ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-I, MacI, pI50.95, VLA-4, ICAM-I, VCAM, EpCAM, alpha4/beta7 integrin, and alpha5/beta3 integrin including either alpha or beta subunits thereof (e.g.
  • anti-CD11a, anti-CD18 or anti-CD11b antibodies growth factors such as VEGF; tissue factor (TF); TGF-beta; alpha interferon (alpha-IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C etc.
  • growth factors such as VEGF; tissue factor (TF); TGF-beta; alpha interferon (alpha-IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C etc.
  • the most concrete targets herein are IGF-IR, CanAg, EphA2, MUC1, MUC16, VEGF, TF, CD19, CD20, CD22, CD27, CD33, CD37, CD38, CD40, CD44, CD56, CD138, CA6, Her2/neu, EpCAM, CRIPTO (a protein produced at elevated levels in a majority of human breast cancer cells), darpins, alpha v /beta 3 integrin, alpha v /beta 5 integrin, alpha v /beta 6 integrin, TGF-beta, CD11a, CD18, Apo2 and C242 or an antibody which binds to one or more tumor-associated antigens or cell-surface receptors disclosed in US Publication No. 20080171040 or US Publication No. 20080305044 and are incorporated in their entirety by reference.
  • CD proteins such as CD3, CD4, CD8, CD19, CD20, CD27, CD34, CD37, CD38, CD46, CD56, CD70 and CD138
  • members of the ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor
  • cell adhesion molecules such as LFA-I, Macl, pI50.95, VLA-4, ICAM-I, VCAM, EpCAM, alpha4/beta7 integrin, and alpha v/beta3 integrin including either alpha or beta subunits thereof (e.g.
  • anti-CD11a, anti-CD 18 or anti-CD11b antibodies growth factors such as VEGF; tissue factor (TF); TGE- ⁇ ; alpha interferon (alpha-IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C, etc.
  • growth factors such as VEGF; tissue factor (TF); TGE- ⁇ ; alpha interferon (alpha-IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C, etc.
  • the most concrete targets herein are IGF-IR, CanAg, EGF-R, EGF-RvIII, EphA2, MUCI, MUC16, VEGF, TF, CD19, CD20, CD22, CD27, CD33, CD37, CD38, CD40, CD44, CD56, CD70, CD 138, CA6, Her2/neu, CRIPTO (a protein produced at elevated levels in a majority of human breast cancer cells), alpha v/beta3 integrin, alpha v/beta5 integrin, TGE- ⁇ , CDI Ia, CD18, Apo2, EpCAM and C242.
  • Monoclonal antibody techniques allow for the production of specific cell-binding agents in the form of monoclonal antibodies.
  • Particularly well known in the art are techniques for creating monoclonal antibodies produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins.
  • Sensitized human cells can also be used.
  • Another method of creating monoclonal antibodies is the use of phage libraries of sFv (single chain variable region), specifically human sFv (see, e.g., Griffiths et al, U.S. Pat. No. 5,885,793; McCafferty et al, WO 92/01047; Liming et al, WO 99/06587.)
  • the monoclonal antibody My9 is a murine IgG2a antibody that is specific for the CD33 antigen found on Acute Myeloid Leukemia (AML) cells (Roy et al. Blood 77:2404-2412 (1991)) and can be used to treat AML patients.
  • the monoclonal antibody anti-B4 is a murine IgGi that binds to the CD 19 antigen on B cells (Nadler et al, J Immunol. 131:244-250 (1983)) and can be used if the target cells are B cells or diseased cells that express this antigen such as in non-Hodgkin's lymphoma or chronic lymphoblastic leukemia.
  • the antibody N901 is a murine monoclonal IgGi antibody that binds to CD56 found on small cell lung carcinoma cells and on cells of other tumors of neuroendocrine origin (Roy et al. J Nat. Cancer Inst. 88:1136-1145 (1996)); huC242 is an antibody that binds to the CanAg antigen; Trastuzumab is an antibody that binds to HER2/neu; and anti-EGF receptor antibody binds to EGF receptor.
  • the drug unit used in this invention can be any cytotoxic, cytostatic or immunosuppressive drug also referred to herein as a cytotoxic, cytostatic or immunosuppressive agent.
  • drugs include radioactive isotopes, chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including synthetic analogues and derivatives thereof.
  • the Drug unit has an atom that can form a bond with the Linker Unit, in some embodiments, the Drug unit has a nitrogen atom that can form a bond with the Linker unit. In other embodiments, the Drug unit has a carboxylic acid that can form a bond with the Linker unit. In other embodiments, the Drug unit has a sulfhydryl group that can form a bond with the Linker unit . In other embodiments, the Drug unit has a hydroxy! group or ketone that can form a bond with the Linker unit.
  • cytotoxic or immunosuppressive agents include, for example, antitubulin agents, auristatins, DNA minor groove binders, DNA replication inhibitors, alkylating agents (e.g. , platinum complexes such as cis-platin, mono(platinum), bis(platinum) and tri-nuelear platinum complexes and carbopiatin), anthracyclin.es, antibiotics, antifolates-, antimetabolites, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas, platinois, pre-formirsg compounds, purine antimetabolites, puromycins, radiation sensitizers, steroids, taxanes, topoisornerase inhibitors, vinca alkaloids, or the like.
  • alkylating agents e.g. , platinum complexes such as cis-platin, mono(p
  • cytotoxic agents include, for example, DNA minor groove binders, DNA alkylating agents, and tubulin inhibitors.
  • cytotoxic agents include, for example, auristatins, camptothecins, duocarmycins, etoposides, maytansines and maytansinoids (e.g., DM! and DM4), taxanes, benzodiazepines (e.g., pyrrolo [1,4] benzodiazepines (PBDs). indolinobenzodiazepines, and oxazolidinobenzodiazepines) and vinca alkaloids.
  • PBDs pyrrolo [1,4] benzodiazepines
  • indolinobenzodiazepines, and oxazolidinobenzodiazepines and vinca alkaloids.
  • Select benzodiazepine containing drugs are described in WO 2010/091 150, WO 2012/1 12708, WO 2007/085930, and WO 201 1/
  • cytotoxic or immunosuppressive agents include, for example, an androgen, antbramycin (AMC), asparaginase, 5-azacytidine, azathioprine, bleomycin, busuJfan, buthionine sulfoximine, calicheamicin, camptothecin, carbopiatin, carmustine (BSNU), CC-1065, chlorambucil, cisplatin, colchicine, cyclophosphamide, cytarabine, cytidine arabinoside, cytochalasin B, dacarbazine, dactinomycin (formerly actinomycin).
  • AMC antbramycin
  • asparaginase 5-azacytidine
  • azathioprine 5-azacytidine
  • azathioprine 5-azacytidine
  • azathioprine 5-azacytidine
  • azathioprine 5-azacytidine
  • azathioprine
  • suitable cytotoxic agents include, for example, DNA minor groove binders (e.g., enediynes and exitropsins, a CBI compound; see also U.S. Pat. No. 6,130,237), duocarmycras (see U.S. Publication No.
  • taxanes e.g., paclitaxei and docetaxel
  • puromycins e.g., vinca alkaloids, CC-1065, SN-38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, echinomvcin, combretastatin, netropsin, epothilone A and B, estramustine, cryptophysins, cemadotin, maytansinoids, discodermoiide, eleutherobin, and mitoxantrone.
  • taxanes e.g., paclitaxei and docetaxel
  • puromycins e.g., vinca alkaloids, CC-1065, SN-38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, echinomvcin, combret
  • the Drug unit is an anti-tubulin agent.
  • anti-tubulin agents include, but are not limited to, taxanes (e.g., Taxol® (paclitaxei), Taxotere ⁇ (docetaxel)), T67 (Tularik) and vinca alkyloids (e.g., vincristine, vinblastine, vindesme, and vinorelbine).
  • antitubulin agents include, for example, baccatin derivatives, taxane analogs (e.g., epothilone A and B), nocodazole, colchicine and colcimid, estramustine, cryptophysins, cemadotin, maytansinoids, combretastatins, discodermoiide, and eleutherobin.
  • the cytotoxic agent is maytansine or a maytansinoid, another group of anti-tubulin agents.
  • maytansine or a maytansinoid, another group of anti-tubulin agents.
  • the Drug unit is an auristatin.
  • Auristatins include, but are not limited to, AE, AFP, AEB, AEVB, MMAF, and MMAE.
  • the synthesis and structure of auristatins are described in U.S. Patent Application Publication Nos. 2003-0083263, 2005-0238649 2005-0009751 , 2009-01 1 1756, and 201 1-0020343: International Patent Publication No. WO 04/010957, international Patent Publication No. WO 02/088172, and U.S. Pat. Nos. 7,659,241 and 8,343,928; each of which is incorporated by reference in its entirety and for all purposes.
  • Exemplary auristatins of the present invention bind tubulin and exert a cytotoxic or cytostatic effect on the desired cell line.
  • Exemplary auristatin Drug units have the following formula or a pharmaceutically acceptable salt thereof wherein the wavy line indicates site of attachment to the linker unit:
  • the Drug is a benzodiazepine (including benzodiazepine containing drugs e.g., pyrrolo[l,4]benzodiazepiries (PBDs), indolinobenzodiazepines, and oxazo!idino benzodiazepines).
  • PBDs are of the general structure:
  • PBDs to form an adduct in the minor groove enables them to interfere with DNA processing, hence their use as antitumour agents.
  • the biological activity of these molecules can be potentiated by, for example, joining two PBD units together through their C8/C -hydroxyl functionalities via a flexible alkylene linker.
  • the PBD dimers are thought to form sequence-selective DNA lesions such as the palindromic 5′-Pu-GATC-Py-3′ interstrand cross-link which is thought to be mainly responsible for their biological activity.
  • An amino alcohol 1 is reacted with a hemiacetal such as trifluoroacetaldehyde methyl hemiacetal in a solvent such as toluene at refluxing temperature with concomitant removal of water to give an oxazolidine intermediate 2.
  • Oxazolidine 2 is then reacted with a Grignard or alkali reagent derived from an appropriate precursor to afford an amino alcohol intermediate 3.
  • Oxidation under an appropriate condition such as Jones reagent or periodic acid with catalytic amount of chromium trioxide and followed by esterifaction furnishes the ester intermediate 4.
  • Appropriate manipulation of functional groups on intermediate 4 affords intermediate 5 with suitable handles for further transformations.
  • the amino alcohol 3 in Method 1 can also be prepared in a diastereo-selective manner as described in Gosselin, F., et. al., Org. Lett. 2004, 6, 641 and Roy, A., et. al., J. Org. Chem. 2006, 71, 4320 to give 3a with high distereoselectivity.
  • the solution was divided equally into to two tubes (10 mL each), and 1 mL DMSO solution of drug-linker intermediate (25 mg/mL) was added to each tube.
  • the ratio of drug-linker intermediate to mAb is 6:1.
  • the reaction was carried out at room temperature for ca 12 hour.
  • solutions from the two tubes were pooled, centrifuged at 5000 rpm for 5 min and loaded onto a Protein A affinity column to remove the un-reacted drug-Ilinker intermediate.
  • the pH of the eluent from the column was adjusted to 6.0 with 1 M Tris buffer.
  • the drug antibody ratio (DAR) was determined by hydrophobic interaction chromatography (HIC) HPLC.
  • the invention is now is further described by examples.
  • the examples given below are for illustration purpose and not meant to limit this invention.
  • the compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis.
  • the examples of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Concrete methods include, but are not limited to, those described below.
  • ADC antibody-drug conjugate
  • aq is aqueous
  • mAb is monoclonal antibody
  • MTMH 1-Maleinimidyl-6-trifluoromethylhex-6-yl with the structure of
  • FIG. 1 showed the antiproliferative activity of Herceptin and different ADCs and the result suggested that the study ADC001 (EXAMPLE 9) and the control ADC-HA showed comparable activity in the inhibition on the growth of breast cancer cell line HCC1954 in vitro. Herceptin alone is ineffective in this assay.
  • FIG. 2 showed the tumor growth curves from each group.
  • the result suggested that the study ADC001 (EXAMPLE 9) and the control ADC-HA displayed comparable activity to inhibit tumor growth in the HCC1954 xenograft mice model.
  • FIGS. 3 and 4 showed the antiproliferative activity of Herceptin and ADCs (ADC002 to ADC006, EXAMPLE 10 to 14) and the result suggested that the study ADCs and the control ADC-HA showed comparable activity in the inhibition on the growth of breast cancer cell line HCC1954 in vitro. Herceptin alone is ineffective in this assay
  • FIGS. 5 to 10 showed the tumor growth curves for control ADC-HA and ADCs (ADC-002 to ADC006, EXAMPLE 10 to 14).
  • FIG. 11 showed the comparison of tumor sizes at termination of the study between control ADC-HA and ADCC-002 to ADC006.
  • FIG. 12 showed the antiproliferative activity of Erbitux, control ADC-EA, ADC007 (EXAMPLE 15) and ADC008 (EXAMPLE 16).
  • FIG. 13 showed the tumor growth curves for control ADC-EA, ADC007 (EXAMPLE 15) and ADC008 (EXAMPLE 16).
  • Step 5 (2S)-Tert-butyl 2-((7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoate
  • Step 6 (2S)-2,5-Dioxopyrrolidin-1-yl-2- ⁇ [7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoro-heptan-2-yl]amino ⁇ -3-methylbutanoate
  • Step 6 (2S)-Tert-butyl 2-((7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoate
  • Step 7 (S)-2-(((R)-7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methyl-butanoic acid, (R)-MTMH-Val and (S)-2-(((S)-7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoic acid, (S)-MTMH-Val
  • Step 4 (S)-Benzyl (1-((4-(hydroxymethyl)phenyl)amino)-5-morpholino-1-oxopentan-2-yl) carbamate
  • Step 4 Methyl 2-(((benzyloxy)carbonyl)amino)-3-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexyl)acrylate
  • Step 5 2-(((Benzyloxy)carbonyl)amino)-3-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclo-hexyl)acrylic acid
  • Step 6 Benzyl (1-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexyl)-3-((4-(hydroxylmethyl)phenyl)amino)-3-oxoprop-1-en-2-yl)carbamate
  • Step 7 tert-Butyl ((trans-4-(2-amino-3-((4-(hydroxymethyl)phenyl)amino)-3-oxopropyl)cyclohexyl)methyl)carbamate
  • Step 1 4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)butanoic acid
  • EXAMPLE 1 Herceptin (240 mg) and drug-linker intermediate MTMH-Val-Cit-PAB-OH (11.3 mg), EXAMPLE 1 was coupled according to the general procedure for conjugation of drug-linker intermediate to herceptin to give the title ADC (168 mg, 70%).
  • Breast cancer cell line HCC1954 was grown in RPM11640 medium supplemented with 10% fetal bovine serum and maintained in an atmosphere of 5% CO 2 in a humidified 37° C. incubator.
  • Epidermoid carcinoma cell line A431 was grown in DMEM medium supplemented with 10% fetal bovine serum and maintained in an atmosphere of 5% CO 2 in a humidified 37° C. incubator.
  • mice 7-8 Week old female NOD-SCID mice were injected with HCC1954 cells subcutaneously. Treatment was started 7 days after cell injection once the mean estimated tumor mass reached 153 mm 3 . Mice were grouped randomly according to the tumor volume and body weight (8 animals per group). Animals were treated with ADCs of this invention (15 mpk), Herceptin (15 mpk) as well as vehicle control on day 0 and day 15. Animals were euthanized on day 28 after the start of treatment, when the tumor volume of vehicle control group reached a mass of 1092 mm 3 .
  • mice 6-8 Week old female Balb/c nude mice were injected with A431 cells subcutaneously. Treatment was started 10 days after cell injection once the mean estimated tumor mass reached 172 mm 3 . Mice were grouped randomly according to the tumor volume and body weight (8 animals per group). Animals were treated with ADCs of this invention (10 mpk), Erbitux (10 mpk) as well as vehicle control on day 0 and day 15. Animals were euthanized on day 25 after the start of treatment, when the tumor volume of vehicle control group reached a mass of 2000 mm 3 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/CN2015/083840, filed on Jul. 13, 2015 and published in English as WO 2016/008392 on Jan. 21, 2016. This application claims the priority to International Application No. PCT/CN2014/082292, filed on Jul. 16, 2014. The entire disclosures of the above applications are incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.
BACKGROUND OF THE INVENTION
Antibody drug conjugates (ADCs) hold the promise as a target specific and effective treatment for a number of diseases e.g. bacterial infection and cancers, but at the same time with an improved systemic side effect profile.
The concept to combine a target specific antibody with a cytotoxic compound is very simple and elegant. An antibody is well known for its ability to recognize an antigen in specific manner and the often insufficient cell killing activity following an immune response, limited its therapeutic potential. On the other hand, cyctotoxic compounds are widely used in the treatment of cancers and their effectiveness are hindered by non-specific systemic adverse events associated with higher dose usage. The combination of an antibody with a cyctoxic compound can therefore lead to a therapeutic agent with enhancing efficacy to the antibody and reduced systemic side effects to the cytotoxic drug, attributing to the target specific delivery by the antibody and minimize of normal tissues from drug exposures.
One of the keys to the success of ADCs relies on the identification of suitable linkers that are stable during circulation in the blood stream, but rapidly cleave to release the cytotoxic compound at the target for cell killing activity. A demonstrated successful example is the linker, such as the one in Adcertris, which incorporates a lysosomal enzymatic cleavable peptide component. The C-terminal amide bond in this part of the linker that can be easily cleaved at target cells by lysosomal enzymes is essential to the drug releasing mechanism. Other amide bonds on the linker if undergo prematurely cleavage may lead to undesirable side effects (Formular B-1).
Figure US10280229-20190507-C00001
This application describes the replacement of the N-terminal amide bond of the lysosomal enzymatic cleavable peptide with an amide surrogate (Formullar B-2). This modification can further improved stability of the resulting ADCs in circulation.
Figure US10280229-20190507-C00002
DESCRIPTION OF THE INVENTION
The present invention provides a linker of formula (I) to connect drugs to antibodies,
Figure US10280229-20190507-C00003
wherein,
  • R is selected from the group consisting of CF2H, CF3, CF2CF3, and PhSO2Me;
  • Q is selected from the group consisting of
Figure US10280229-20190507-C00004
  • L1 is selected from the group consisting of —(CR1R2)m—(CR3R4)—(CR1R2)n—, —(CR1R2)m—(CR3R4)—O—(CR1R2)n—, and —[(CR1R2)(CR1R2)X]p—(CR1R2)q—;
  • m is 1, 2, 3, or 4;
  • n is 1, 2, 3, or 4;
  • p is 1, 2, 3, 4, 5, or 6;
  • q is 1 or 2;
  • R1 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2.
  • R2 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • R3 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • R4 is selected from the group consisting of H, C1-3 alkyl, OH, NR5R6, CO2H, P(O)(OH)2, and SO3H, said C1-3 alkyl is optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • R5 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • R6 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • X is selected from the group consisting of NR7, O, S(O)r;
  • r is 0, 1, or 2;
  • R7 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • L2 is a di-peptide unit selected from
Figure US10280229-20190507-C00005
  • R8 is selected from the group consisting of methyl, propyl, isopropyl, sec-butyl, benzyl, and
Figure US10280229-20190507-C00006
  • R9 is selected from the group consisting of (CH2)4NH2, (CH2)3NHCONH2, (CH2)3NHC(═NH)NH2,
Figure US10280229-20190507-C00007
s is 0, 1, 2, 3, or 4;
  • L3 is a self-immolative unit selected from the group consisting of
Figure US10280229-20190507-C00008
  • R10 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • each R11 is independently selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
  • two geminal R11 may be optionally joined together to form a 3-6 membered ring with a carbon atom to which they are attached;
  • two adjacent R11 may be optionally joined together to form a 5-7 membered ring with a carbon atom to which they are attached;
  • R12 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2; and
  • R13 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2.
The present invention also provides a drug-linker conjugate of formula (II),
Figure US10280229-20190507-C00009
wherein,
  • Q′ is selected from the group consisting of
Figure US10280229-20190507-C00010
  • M is a drug; and
    other variables are as defined above.
The present invention also provides an ADC of formula (III),
Figure US10280229-20190507-C00011
wherein,
  • Y is an antibody;
  • a is an integer or decimal selected from 1-8;
  • M is a drug; and
    other variables are as defined in above.
In certain embodment of this invention, a is 1, 2, 3, 3.4, 3.5, 4, 4.2, 5, 6, 7, or 8.
In certain embodment of this invention, the aforesaid antibody is selected from the group consisting of a resurfaced monoclonal antibody, a resurfaced single chain monoclonal antibody, or a resurfaced monoclonal antibody fragment that preferentially binds to a target cell.
In certain embodment of this invention, the aforesaid antibody is selected from the group consisting of a humanized monoclonal antibody, a humanized single chain monoclonal antibody, or a humanized monoclonal antibody fragment.
In certain embodment of this invention, the aforesaid antibody is selected from the group consisting of a chimeric antibody, a chimeric antibody fragment, a domain antibody, or a domain antibody fragment thereof.
In certain embodment of this invention, the aforesaid antibody is selected from the group consisting of MY9, anti-B4, EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFR, EGFRvIII, HER2, HER3, mesothelin, cripto, alphavbeta3, alphavbeta5, alphavbeta6 integrin or C242.
In certain embodment of this invention, the aforesaid antibody is selected from the group consisting of My9-6, B4, C242, N901, DS6, EphA2 receptor, CD38, IGF-IR, CNTO 95, B-B4, Trastuzumab, Tertuzumab, Bevatuzumab, Sibrotuzumab, Rituximab, and Adalimumab.
In certain embodment of this invention, the aforesaid antibody is selected from the group consisting of Herceptin and Erbitux.
In certain embodment of this invention, the aforesaid antibody binds to target cells selected from tumor cells; virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing one or more of IGF-IR, CanAg, EGFR, MUCI, MUCI 6, VEGF, TF, MY9, anti-B4, EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD11a, CD18, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD70, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFRvIII, HER2/neu, HER3, mesothelin, cripto, alphavbeta3 integrin, alphavbeta5 integrin, alphavbeta6 integrin, Apo2, and C242 antigens; or cells expressing insulin growth factor receptor, epidermal growth factor receptor, and folate receptor.
In certain embodment of this invention, the aforesaid tumor cells are selected from breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, and testicular cancer cells.
In certain embodment of this invention, the aforesaid drug is a cytotoxic drug.
In certain embodment of this invention, the aforesaid drug is selected from the group consisting of maytansinoid, DNA-binding drug and its analog, calicheamicin, doxorubicin and its analog, vinca alkaloid, cryptophycin, dolastatin, auristatin and analog thereof, tubulysin, epothilone, taxoid and siRNA.
In certain embodment of this invention, the aforesaid DNA-binding drug is CC-1065.
In certain embodment of this invention, the aforesaid M is selected from the group consisting of:
Figure US10280229-20190507-C00012
In certain embodment of this invention, the aforesaid drug is a diagnostic or detection reagen.
In certain embodment of this invention, the aforesaid drug is a radio-labeled compound.
In certain embodment of this invention, the aforesaid drug is labeled with 3H, 18F, 11C, 13N, 15O, 201Tl, 32P, 51Cr, 67Ga, 123I, 125I, 131I, 132I, 131Cs, 113Xe, 133Xe, 169Yb, 198Au, 203Hg, 99mTc, 113mIn, 133mIn, 75Se, 186Re, 153Sm, and 89Sr.
In certain embodment of this invention, the aforesaid L1 is selected from the group consisting of:
Figure US10280229-20190507-C00013
In certain embodment of this invention, the aforesaid L2 is selected from the group consisting of:
Figure US10280229-20190507-C00014
In certain embodment of this invention, the aforesaid L2 is selected from the group consisting of:
Figure US10280229-20190507-C00015
In certain embodment of this invention, the aforesaid ring formed by two geminal R11 or two adjacent R11 is cyclohexyl.
In certain embodment of this invention, the aforesaid L3 is selected from the group consisting of:
Figure US10280229-20190507-C00016
In certain embodment of this invention, the aforesaid moiety of
Figure US10280229-20190507-C00017
is selected from the group consisting of:
Figure US10280229-20190507-C00018
In certain embodment of this invention, the aforesaid moiety of
Figure US10280229-20190507-C00019
is selected from the group consisting of:
Figure US10280229-20190507-C00020
In certain embodment of this invention, the aforesaid linker is selected from the group consisting of:
Figure US10280229-20190507-C00021
Figure US10280229-20190507-C00022
In certain embodment of this invention, the aforesaid linker is selected from the group consisting of:
Figure US10280229-20190507-C00023
Figure US10280229-20190507-C00024
Figure US10280229-20190507-C00025
In certain embodment of this invention, the aforesaid conjugate is selected from the group consisting of:
Figure US10280229-20190507-C00026
Figure US10280229-20190507-C00027
In certain embodment of this invention, the aforesaid conjugate is selected from the group consisting of:
Figure US10280229-20190507-C00028
Figure US10280229-20190507-C00029
Figure US10280229-20190507-C00030
In certain embodment of this invention, the aforesaid ADC is selected from the group consisting of:
Figure US10280229-20190507-C00031
Figure US10280229-20190507-C00032
Y is an antibody, a is an integer or decimal selected from 1-8, concretely a is 1, 2, 3, 3.4, 3.5, 4, 4.2, 5, 6, 7, or 8.
In certain embodment of this invention, the aforesaid ADC is selected from the group consisting of:
Figure US10280229-20190507-C00033
Figure US10280229-20190507-C00034
Figure US10280229-20190507-C00035
Y is an antibody, a is an integer or decimal selected from 1-8, concretely a is 1, 2, 3, 3.4, 3.5, 4, 4.2, 5, 6, 7, or 8.
In certain embodment of this invention, the aforesaid ADC is selected from the group consisting of:
Figure US10280229-20190507-C00036
Figure US10280229-20190507-C00037
Figure US10280229-20190507-C00038
a is an integer or decimal selected from 2-6, concretely a is 2, 3, 3.4, 3.5, 4, 4.2, 5, or 6.
In certain embodment of this invention, the aforesaid ADC is selected from the group consisting of:
Figure US10280229-20190507-C00039
Figure US10280229-20190507-C00040
Figure US10280229-20190507-C00041
Figure US10280229-20190507-C00042
a is an integer or decimal selected from 2-6, concretely a is 2, 3, 3.4, 3.5, 4, 4.2, 5, or 6.
The present invention also provides intermediate compound for the synthesis of the drug-linker conjugate of formula (II) or the ADC of formula (III), comprising:
Figure US10280229-20190507-C00043
Figure US10280229-20190507-C00044
The present invention also provides a pharmaceutical composition comprising an effective amount of the aforesaid ADC and a pharmaceutically acceptable carrier, diluent or excipient.
The present invention also provides a use of the aforesaid linker, conjugate, or ADC or the aforesaid composition in the preparation of a medicament for the treatment of cancers.
The present invention also provides a method for treating or diagnosising cancers, comprising administrating the subject in need thereof an effective amount of the aforesaid ADC or the aforesaid pharmaceutical composition.
Definitions and Explanations
C1-6 is selected from the group consisting of C1, C2, C3, C4, C5, and C6, the number denotes numbers of carbon atoms; C3-6 is selected from the group consisting of C3, C4, C5, and C6.
C1-6 alkyl, C1-6 heteroalkyl, C3-6 cyclohydrocarbyl, C3-6 heterocyclohydrocarbyl, C1-6 alkyl substituted by C3-6 cyclohydrocarbyl or C3-6 heterocyclohydrocarbyl, and C1-6 heteroalkyl substituted by C3-6 cyclohydrocarbyl or C3-6 heterocyclohydrocarbyl include, but are not limited to: methyl, ethyl, n-propyl, isopropyl, —CH2C(CH3)(CH3)(OH), cyclopropyl, cyclobutyl, propylmethylene, cycropropylacyl, benzyloxyl, cyclopropylalkylene, trifluoromethyl, aminomethyl, hydroxylmethyl, methyloxyl, methylacyl, methyloxylcarbonyl, methylsulfonyl, methylsulfinyl, ethyloxyl, ethylacyl, ethylsulfonyl, ethyloxylcarbonyl, dimethylamino, diethylamino, dimethylaminocarbonyl, and diethylaminocarbonyl;
N(CH3)2, NH(CH3), —CH2CF3, —CH2CH2CF3, —CH2CH2F, —CH2CH2S(═O)2CH3, —CH2CH2CN,
Figure US10280229-20190507-C00045
—CH2CH(OH)(CH3)2, —CH2CH(F)(CH3)2, —CH2CH2F, —CH2CF3, —CH2CH2CF3, —CH2CH2NH2, —CH2CH2OH, —CH2CH2OCH3, —CH2CH2CH2OCH3, —CH2CH2N(CH3)2, —S(═O)2CH3, —CH2CH2S(═O)2CH3, , , ,
Figure US10280229-20190507-C00046
The term “substituted”, as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, including deuterium “D” atom, a variant of hydrogen, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., ═O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. The term “optionally substituted”, as used herein, means that the designated atom can be substituted or unsubstituted by the substituents, and unless otherwise stated, the species and number the substituents are not defined provided that they can be achieved in Chemistry.
When any variable (e.g., R) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R, then said group may optionally be substituted with up to two R groups and R at each occurrence is selected independently from the definition of R. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are generically referred to as “alkyl group substituents,” and they can be one or more of a variety of groups selected from, but not limited to: —R′, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″,
—SR′, -halogen, —SiR′R″R′″, OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″,
—OC(O)NR′R″, —NR″C(O)R′, NR′C(O)NR″R′″, —NR″C(O)2R′,
—NR′″″—C(NR′R″R′″)═NR″″, NR″″ C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′,
—S(O)2NR′R″, NR″SO2R′, —CN, —NO2, —N3, —CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1-C4)alkyl, in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″, R′″, R″″ and R′″″ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, R″″ and R′″″ groups when more than one of these groups is present. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, —NR′R″ is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like).
Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are generically referred to as “aryl group substituents.” The substituents are selected from, for example: —R′, —OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, NR′ C(O)NR″R′″, —NR″C(O)2R′, —NR′″″—C(NR′R″R′″)═NR″″, NR″″ C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, NR″SO2R′, —CN, —NO2, —N3, —CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R′, R″, R′″, R″″ and R′″″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, R″″ and R′″″ groups when more than one of these groups is present.
Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)—(CRR′)q-U—, wherein T and U are independently —NR—, —O—, —CRR′— or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A(CH2)r B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, S(O)2—, —S(O)2NR′— or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′)s-X—(CR″R′″)d-, where s and d are independently integers of from 0 to 3, and X is —O—, —NR′—, —S—, —S(O)—, —S(O)2—, or —S(O)2NR′—. The substituents R, R′, R″ and R′″ are preferably independently selected from hydrogen or substituted or unsubstituted (C1-C6)alkyl.
The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C1-C4)alkyl” is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.“Alkoxy”represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. C1-6 alkoxy, is intended to include C1, C2, C3, C4, C5, and C6 alkoxy groups. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. “Cycloalkyl” is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. 3-7 cycloalkyl is intended to include C3, C4, C5, C6, and C7 cycloalkyl groups. Alkenyl” is intended to include hydrocarbon chains of either straight or branched configuration and one or more unsaturated carbon-carbon bonds that may occur in any stable point along the chain, such as ethenyl and propenyl.
“Halo” or “halogen” as used herein refers to fluoro, chloro, bromo, and iodo.
As used herein, the term “hetero” , mean, unless otherwise stated, “heteroatom” or “heteroradical”(namely radical containing heteroatom), includeing atoms other than carbon (C) and hydrogen (H), also including the radicals containing these aforesaid heteroatoms. Examples include oxygen (O), nitrogen (N) sulfur (S), silicon (Si), germanium (Ge), aluminum (Al) and boron (B), also include optionally substituted —C(═O)N(H)—, —N(H)—, —C(═NH)—, —S(═O)2 N(H)—, or —S(═O) N(H)—.
“Ring” as used herein, means a substituted or unsubstituted cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, heterocycloalkynyl, aryl, or heteroaryl. A ring includes mono, bi, sprio, fused, and bridged ring moieties. The number of atoms in a ring is typically defined by the number of members in the ring. For example, a “5- to 7-membered ring” means there are 5 to 7 atoms in the encircling arrangement. Unless otherwise specified, the ring optionally includes one to three heteroatoms. Thus, the term “5- to 7-membered ring” includes, for example phenyl, pyridinyl and piperidinyl. The term “5- to 7-membered heterocycloalkyl ring”, on the other hand, would include pyridinyl and piperidinyl, but not phenyl. The term “ring” further includes a ring system comprising more than one “ring”, wherein each “ring” is independently defined as above.
As used herein, the term “heterocycle” or “heterocyclic group” is intended to mean a stable monocyclic, bicyclic, or tricyclic ring containing heteroatom or heteroradical, which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1,2, 3, or 4 ring heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., NO and S (O) p). The nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined). The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term “aromatic heterocyclic group”or“heteroaryl”is intended to mean a stable 5,6, or 7-membered monocyclic or bicyclic or 7,8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1,2, 3, or 4 heterotams independently selected from the group consisting of N, O and S. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., NO and S (O) p). It is to be noted that total number of S and 0 atoms in the aromatic heterocycle is not more than 1. Bridged rings are also included in the definition of heterocycle. A bridged ring occurs when one or more atoms (i.e., C, O, N, or S) link two non-adjacent carbon or nitrogen atoms. Preferred bridges include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a trycyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1, 5,2-dithiazinyl, dihydrofuro [2, 3-b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2, 5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2, 3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
The term “hydrocarbyl” or its lower concept(such as alkyl, alkenyl, alkynyl and phenyl etc.) by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. C1-C10 means one to ten carbons). “Hydrocarbyl” include, but are not limited to, aliphatic hydrocarbyl and aromatic hydrocarbyl, and the aliphatic hydrocarbyl include linear and cyclic ones, specifically including but not limited to, alkyl, alkenyl, and alkynyl, and the aromatic hydrocarbyl include, but are not limited to, 6-12 membered aromatichydrocarbyl, for example, benzene, and naphthalene. In some embodiments, the term “alkyl” means a straight or branched chain, or combinations thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
The term “heterohydrocarbyl” or its lower concept (such as heteroalkyl, heteroalkenyl, teteroalkynyl and heteroaryl etc.) by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom. In some embodiments, the term “heteroalkyl,” by itself or in combination with another term, means a stable straight or branched chain, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom. In an exemplary embodiment, the heteroatoms can be selected from the group consisting of B, O, N and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) B, O, N and S may be placed at any interior position of the heterohydrocarbyl group(including the position at which the hydrocarbyl group is attached to the remainder of the molecule). Examples include, but are not limited to, —CH2-CH2-O—CH3, —CH2-CH2-NH—CH3, —CH2-CH2-N(CH3)-CH3, —CH2-S—CH2-CH3, —CH2-CH2,—S(O)—CH3, —CH2-CH2-S(O)2-CH3, —CH═CH—O—CH3, —CH2-CH═N—OCH3, and —CH═CH—N(CH3)-CH3. Up to two heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3.
The terms “alkoxy,” “alkylamino” and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
The terms “cyclohydrocarbyl”, “heterocyclohydrocarbyl”, or their lower concepts(such as aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, and heterocycloalkynyl etc.) by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “hydrocarbyl” or “heterohydrocarbyl”, respectively. Additionally, for heterohydrocarbyl or heterocyclohydrocarbyl(such as heteroalkyl and heterocycloalkyl), a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Non-limiting examples of heterocycloalkyl moieties include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl.
The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently. The term “heteroaryl” refers to aryl groups (or rings) that contain from one to four heteroatoms. In an exemplary embodiment, the heteroatom is selected from B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
For brevity, the term “aryl” when used in combination with other terms (e.g., aryloxy, arylthio, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term “arylalkyl” is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like).
The term “leaving group” means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction. By way of example, representative leaving groups include triflate, chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
The term “protecting group” includes bu not limited to “amino-protecting group”, “hydroxy-protecting group” and “thiol-protecting group”. The term “amino-protecting group” means a protecting group suitable for preventing undesired reactions at an amino nitrogen. Representative amino-protecting groups include, but are not limited to, formyl; acyl groups, for example alkanoyl groups, such as acetyl, trichloroacetyl or trifluoroacetyl; alkoxycarbonyl groups, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl groups, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups, such as benzyl (Bn), trityl (Tr), and 1,1-di-(4′-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); and the like. The term “hydroxy-protecting group” means a protecting group suitable for preventing undesired reactions at a hydroxy group. Representative hydroxy-protecting groups include, but are not limited to, alkyl groups, such as methyl, ethyl, and tert-butyl; acyl groups, for example alkanoyl groups, such as acetyl; arylmethyl groups, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), and diphenylmethyl (benzhydryl, DPM); silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); and the like.
Where the “antibody” is a cell-binding agent, it binds to an antigen that is a polypeptide and may be a transmembrane molecule (e.g. receptor) or a ligand such as a growth factor.
Exemplary antigens include molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor vmc, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha); a serum albumin, such as human serum albumin; Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as beta-lactamase; DNase; IgE; a cytotoxic T-lymphocyte associated antigen (CTLA), such as CTLA-4; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; protein A or D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT4, NT-5, or NT-6), or a nerve growth factor such as NGF-β; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-alpha and TGF-beta, including TGF-β, TGF-β2, TGF-beta]3, TGF-β4, or TGF-beta5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(I-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins, EpCAM, GD3, FLT3, PSMA, PSCA, MUCI , MUC16, STEAP, CEA, TENB2, EphA receptors, EphB receptors, folate receptor, FOLRI, mesothelin, cripto, alphavbetae, integrins, VEGF, VEGFR, tarnsferrin receptor, IRTAI, IRTA2, IRTA3, IRTA4, IRTA5; CD proteins such as CD2, CD3, CD4, CD5, CD6, CD8, CDI 1 , CD14, CDI 9, CD20, CD21, CD22, CD23, CD25, CD26, CD28, CD30, CD33, CD36, CD37, CD38, CD40, CD44, CD52, CD55, CD56, CD59, CD70, CD79, CD80, CD81 , CDI 03, CDI 05, CDI 34, CDI 37, CDI 38, CDI 52; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon, such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-I to IL-IO; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigen such as, for example, a portion of the HIV envelope; transport proteins; homing receptors; addressins; regulatory proteins; integrins, such as CDI Ia, CDI Ib, CDI Ic, CDI 8, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as HER2, HER3 or HER4 receptor; and fragments of any of the above-listed polypeptides, antibody mimics Adnectins (US appl 20070082365), or an antibody which binds to one or more tumor-associated antigens or cell-surface receptors disclosed in US Publication No. 20080171040 or US Publication No. 20080305044 and are incorporated in their entirety by reference.
Concrete antigens for antibodies encompassed by the present invention include CD proteins such as CD2, CD3, CD4, CD5, CD6, CD8, CD11, CD14, CD18, CD19, CD20, CD21, CD22, CD 25, CD26, CD27, CD28, CD30, CD33, CD36, CD37, CD38, CD40, CD44, CD52, CD55, CD56, CD70, CD79, CD80, CD81, CD103, CD105, CD134, CD137, CD138, and CD152; members of the ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-I, MacI, pI50.95, VLA-4, ICAM-I, VCAM, EpCAM, alpha4/beta7 integrin, and alpha5/beta3 integrin including either alpha or beta subunits thereof (e.g. anti-CD11a, anti-CD18 or anti-CD11b antibodies); growth factors such as VEGF; tissue factor (TF); TGF-beta; alpha interferon (alpha-IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C etc.
The most concrete targets herein are IGF-IR, CanAg, EphA2, MUC1, MUC16, VEGF, TF, CD19, CD20, CD22, CD27, CD33, CD37, CD38, CD40, CD44, CD56, CD138, CA6, Her2/neu, EpCAM, CRIPTO (a protein produced at elevated levels in a majority of human breast cancer cells), darpins, alphav/beta3 integrin, alphav/beta5 integrin, alphav/beta6 integrin, TGF-beta, CD11a, CD18, Apo2 and C242 or an antibody which binds to one or more tumor-associated antigens or cell-surface receptors disclosed in US Publication No. 20080171040 or US Publication No. 20080305044 and are incorporated in their entirety by reference.
Concrete antigens for antibodies encompassed by the present invention also include CD proteins such as CD3, CD4, CD8, CD19, CD20, CD27, CD34, CD37, CD38, CD46, CD56, CD70 and CD138; members of the ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-I, Macl, pI50.95, VLA-4, ICAM-I, VCAM, EpCAM, alpha4/beta7 integrin, and alpha v/beta3 integrin including either alpha or beta subunits thereof (e.g. anti-CD11a, anti-CD 18 or anti-CD11b antibodies); growth factors such as VEGF; tissue factor (TF); TGE-β; alpha interferon (alpha-IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C, etc. The most concrete targets herein are IGF-IR, CanAg, EGF-R, EGF-RvIII, EphA2, MUCI, MUC16, VEGF, TF, CD19, CD20, CD22, CD27, CD33, CD37, CD38, CD40, CD44, CD56, CD70, CD 138, CA6, Her2/neu, CRIPTO (a protein produced at elevated levels in a majority of human breast cancer cells), alpha v/beta3 integrin, alpha v/beta5 integrin, TGE-β, CDI Ia, CD18, Apo2, EpCAM and C242.
Monoclonal antibody techniques allow for the production of specific cell-binding agents in the form of monoclonal antibodies. Particularly well known in the art are techniques for creating monoclonal antibodies produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins. Sensitized human cells can also be used. Another method of creating monoclonal antibodies is the use of phage libraries of sFv (single chain variable region), specifically human sFv (see, e.g., Griffiths et al, U.S. Pat. No. 5,885,793; McCafferty et al, WO 92/01047; Liming et al, WO 99/06587.)
Selection of the antibody is a matter of choice that depends upon the particular cell population that is to be targeted, but in general monoclonal antibodies and epitope binding fragments thereof are preferred, if an appropriate one is available.
For example, the monoclonal antibody My9 is a murine IgG2a antibody that is specific for the CD33 antigen found on Acute Myeloid Leukemia (AML) cells (Roy et al. Blood 77:2404-2412 (1991)) and can be used to treat AML patients. Similarly, the monoclonal antibody anti-B4 is a murine IgGi that binds to the CD 19 antigen on B cells (Nadler et al, J Immunol. 131:244-250 (1983)) and can be used if the target cells are B cells or diseased cells that express this antigen such as in non-Hodgkin's lymphoma or chronic lymphoblastic leukemia. The antibody N901 is a murine monoclonal IgGi antibody that binds to CD56 found on small cell lung carcinoma cells and on cells of other tumors of neuroendocrine origin (Roy et al. J Nat. Cancer Inst. 88:1136-1145 (1996)); huC242 is an antibody that binds to the CanAg antigen; Trastuzumab is an antibody that binds to HER2/neu; and anti-EGF receptor antibody binds to EGF receptor.
The drug unit used in this invention can be any cytotoxic, cytostatic or immunosuppressive drug also referred to herein as a cytotoxic, cytostatic or immunosuppressive agent. Examples of drugs include radioactive isotopes, chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including synthetic analogues and derivatives thereof. The Drug unit has an atom that can form a bond with the Linker Unit, in some embodiments, the Drug unit has a nitrogen atom that can form a bond with the Linker unit. In other embodiments, the Drug unit has a carboxylic acid that can form a bond with the Linker unit. In other embodiments, the Drug unit has a sulfhydryl group that can form a bond with the Linker unit . In other embodiments, the Drug unit has a hydroxy! group or ketone that can form a bond with the Linker unit.
Useful classes of cytotoxic or immunosuppressive agents include, for example, antitubulin agents, auristatins, DNA minor groove binders, DNA replication inhibitors, alkylating agents (e.g. , platinum complexes such as cis-platin, mono(platinum), bis(platinum) and tri-nuelear platinum complexes and carbopiatin), anthracyclin.es, antibiotics, antifolates-, antimetabolites, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas, platinois, pre-formirsg compounds, purine antimetabolites, puromycins, radiation sensitizers, steroids, taxanes, topoisornerase inhibitors, vinca alkaloids, or the like. Particularly examples of useful classes of cytotoxic agents include, for example, DNA minor groove binders, DNA alkylating agents, and tubulin inhibitors. Exemplary cytotoxic agents include, for example, auristatins, camptothecins, duocarmycins, etoposides, maytansines and maytansinoids (e.g., DM! and DM4), taxanes, benzodiazepines (e.g., pyrrolo [1,4] benzodiazepines (PBDs). indolinobenzodiazepines, and oxazolidinobenzodiazepines) and vinca alkaloids. Select benzodiazepine containing drugs are described in WO 2010/091 150, WO 2012/1 12708, WO 2007/085930, and WO 201 1/023883.
Individual cytotoxic or immunosuppressive agents include, for example, an androgen, antbramycin (AMC), asparaginase, 5-azacytidine, azathioprine, bleomycin, busuJfan, buthionine sulfoximine, calicheamicin, camptothecin, carbopiatin, carmustine (BSNU), CC-1065, chlorambucil, cisplatin, colchicine, cyclophosphamide, cytarabine, cytidine arabinoside, cytochalasin B, dacarbazine, dactinomycin (formerly actinomycin). daunorubicin, decarbazine, docetaxel, doxorubicin, etoposide, an estrogen, 5-fluordeoxyuridine, 5˜fluorouracil, gemcitabine, gramicidin D, hydroxyurea, idarubicin, ifosfamide, irinoteean, iomustine (CCNU), mayiansine, mechlorethainine, melphalan, 6-mercaptopurine, methotrexate, mithramycin, mitomycin C, mitoxantrone, nitroimidazole, paclitaxei, paly toxin, plicamycin, procarbizine, rhizoxin, streptozotocin, tenoposide, 6-thioguanine, thioTEPA, topotecan, vinblastine, vincristine, vinorelbine, VP-16 and VM-26.
In certain typical embodiments, suitable cytotoxic agents include, for example, DNA minor groove binders (e.g., enediynes and exitropsins, a CBI compound; see also U.S. Pat. No. 6,130,237), duocarmycras (see U.S. Publication No. 20060024317), taxanes (e.g., paclitaxei and docetaxel), puromycins, vinca alkaloids, CC-1065, SN-38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, echinomvcin, combretastatin, netropsin, epothilone A and B, estramustine, cryptophysins, cemadotin, maytansinoids, discodermoiide, eleutherobin, and mitoxantrone.
In certain embodiments, the Drug unit is an anti-tubulin agent. Examples of anti-tubulin agents include, but are not limited to, taxanes (e.g., Taxol® (paclitaxei), Taxotere© (docetaxel)), T67 (Tularik) and vinca alkyloids (e.g., vincristine, vinblastine, vindesme, and vinorelbine). Other antitubulin agents include, for example, baccatin derivatives, taxane analogs (e.g., epothilone A and B), nocodazole, colchicine and colcimid, estramustine, cryptophysins, cemadotin, maytansinoids, combretastatins, discodermoiide, and eleutherobin.
In certain embodiments, the cytotoxic agent is maytansine or a maytansinoid, another group of anti-tubulin agents. (ImmunoGen, Inc.: see also Chari et ah, 1992, Cancer Res. 52:127-131 and U.S. Pat. No. 8,163,888).
In certain embodiments, the Drug unit is an auristatin. Auristatins include, but are not limited to, AE, AFP, AEB, AEVB, MMAF, and MMAE. The synthesis and structure of auristatins are described in U.S. Patent Application Publication Nos. 2003-0083263, 2005-0238649 2005-0009751 , 2009-01 1 1756, and 201 1-0020343: International Patent Publication No. WO 04/010957, international Patent Publication No. WO 02/088172, and U.S. Pat. Nos. 7,659,241 and 8,343,928; each of which is incorporated by reference in its entirety and for all purposes. Exemplary auristatins of the present invention bind tubulin and exert a cytotoxic or cytostatic effect on the desired cell line.
Exemplary auristatin Drug units have the following formula or a pharmaceutically acceptable salt thereof wherein the wavy line indicates site of attachment to the linker unit:
Figure US10280229-20190507-C00047
In certain embodiments, the Drug is a benzodiazepine (including benzodiazepine containing drugs e.g., pyrrolo[l,4]benzodiazepiries (PBDs), indolinobenzodiazepines, and oxazo!idino benzodiazepines). PBDs are of the general structure:
Figure US10280229-20190507-C00048
but can differ in the number, type and position of substituents, in both their aromatic A rings and pyrrolo C rings, and in the degree of saturation of the C ring. In the B-ring there is either an imine (N═), a carbinolamine(NH—CH(OH))> or a carbinolamine methyl ether (NH—CH(OMe)) at the N10-C1 1 position, which is the electrophilic center responsible for alkylating DNA. All of the known natural products have a (S)-configuration at the chiral CI la position which provides them vvitli a right-handed twist when viewed from the C ring towards the A ring. This gives them the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a. snug fit at the binding site. The ability of PBDs to form an adduct in the minor groove enables them to interfere with DNA processing, hence their use as antitumour agents. The biological activity of these molecules can be potentiated by, for example, joining two PBD units together through their C8/C -hydroxyl functionalities via a flexible alkylene linker. The PBD dimers are thought to form sequence-selective DNA lesions such as the palindromic 5′-Pu-GATC-Py-3′ interstrand cross-link which is thought to be mainly responsible for their biological activity.
General Method to Prepare Linkers, Drug-Linker Conjugates and ADCs:
Method 1
Figure US10280229-20190507-C00049
An amino alcohol 1 is reacted with a hemiacetal such as trifluoroacetaldehyde methyl hemiacetal in a solvent such as toluene at refluxing temperature with concomitant removal of water to give an oxazolidine intermediate 2. Oxazolidine 2 is then reacted with a Grignard or alkali reagent derived from an appropriate precursor to afford an amino alcohol intermediate 3. Oxidation under an appropriate condition such as Jones reagent or periodic acid with catalytic amount of chromium trioxide and followed by esterifaction furnishes the ester intermediate 4. Appropriate manipulation of functional groups on intermediate 4 affords intermediate 5 with suitable handles for further transformations.
Method 2
Figure US10280229-20190507-C00050
The amino alcohol 3 in Method 1 can also be prepared in a diastereo-selective manner as described in Gosselin, F., et. al., Org. Lett. 2004, 6, 641 and Roy, A., et. al., J. Org. Chem. 2006, 71, 4320 to give 3a with high distereoselectivity.
Method 3
Figure US10280229-20190507-C00051
Amino acid 7 is protected with an appropriate protecting group on the amino moiety and then coupling with 4-amino benzyl alcohol to give intermediate 8 in a standard manner. The protecting group on the amine is then removed to give intermediate 9.
Method 4
Figure US10280229-20190507-C00052
Intermediate 5 or 6 from Method 1 and intermediate 8 from Method 3 is reacted under an appropriate condition to give intermediate 10. Intermediate 10 is then converted to the 4-nitrophenyl carbonate intermediate 11.
Method 5
Figure US10280229-20190507-C00053
Intermediate 11 from Method 4 is reacted with MMAE under an appropriate condition to give linker-drug intermediate 12.
Method 6
Figure US10280229-20190507-C00054
Intermediate 12 is coupled with the desired antibody under an appropriate condition as described in the corresponding experimental section.
General Procedure for Conjugation of Drug-Linker Intermediate to Herceptin:
Step 1: Reduction of Disulfide Bond of Antibody and Purification
To produce 240 mg ADC, 8.955 mL Hereceptin (26.8 mg/mL, around 30 mg·mL) was mixed with 8.95 μL 0.5 M TCEP (final concentration of TCEP in reaction mixture was 0.5 mM), and the reaction was performed at room temperature for 2 hour. Then the reaction solution was loaded on an 1 mL Protein A affinity column to get rid of the remained TCEP and other non-mAb impurities. After the purification, pH of the eluent was adjusted to around 6.0 with 1 M Tris, and the concentration of mAb was measured by nanodrop. The final volume of the solution was about 20 mL, and mAb concentration was 11.6 mg/mL.
Step 2: Conjugation of Drug-Linker and Antibody
The solution was divided equally into to two tubes (10 mL each), and 1 mL DMSO solution of drug-linker intermediate (25 mg/mL) was added to each tube. The ratio of drug-linker intermediate to mAb is 6:1. The reaction was carried out at room temperature for ca 12 hour. When finished, solutions from the two tubes were pooled, centrifuged at 5000 rpm for 5 min and loaded onto a Protein A affinity column to remove the un-reacted drug-Ilinker intermediate. The pH of the eluent from the column was adjusted to 6.0 with 1 M Tris buffer. The drug antibody ratio (DAR) was determined by hydrophobic interaction chromatography (HIC) HPLC.
The invention is now is further described by examples. The examples given below are for illustration purpose and not meant to limit this invention. The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The examples of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Concrete methods include, but are not limited to, those described below.
All solvents used are commercially available and are used without further purification. Reactions are typically run using anhydrous solvents under an inert atmosphere of nitrogen. Proton NMR are recorded on Bruker Avance III 400 (400 MHz) spectrometer and chemical shifts are reported as (ppm) down field from tetramethylsilane. Mass spectra are determined on Agilent 1200 series plus 6110 (& 1956A). LC/MS, or Shimadzu MS consisting of a DAD: SPD-M20A (LC) and Shimadzu Micromass 2020 detector. The mass spectrometer is equipped with an electrospray ion source (ESI) operated in a positive or negative mode.
The following abbreviations are used: ADC is antibody-drug conjugate;aq is aqueous; mAb is monoclonal antibody; MTMH is 1-Maleinimidyl-6-trifluoromethylhex-6-yl with the structure of
Figure US10280229-20190507-C00055
(S)-MTMH is
Figure US10280229-20190507-C00056
(R)-MTMH is
Figure US10280229-20190507-C00057
PABO(CO) is
Figure US10280229-20190507-C00058
ABA is
Figure US10280229-20190507-C00059
MMAE is
Figure US10280229-20190507-C00060
Fmoc-Cl is 9-fluorenylmethyl chloroformate; DIAD is diisopropyl azodicarboxylate; Z-Glu-OMe is (S)-4-(((benzyloxy)carbonyl)amino)-5-methoxy-5-oxopentanic acid; HATU is 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; EDCl is 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; DMSO is Dimethyl sulfoxide; HOBT is Hydroxybenzotriazole; DCM is dichloromethane; PE is petroleum ether; DMF is N,N-dimethylformamide; DMSO is dimethylsulfoxide; EtOAc is ethyl acetate; EtOH is ethanol; MeOH is methanol; Cbz is benzyloxycarbonyl, a amine protecting group; BOC is tert-butylcarbonyl, amine protecting group; HOAc is acetic acid; NaBH(OAc)3 is sodium triacetoxyborohydride; r.t. is room temperature; THF is tetrahydrofuran; Boc2O is di-tert-butyl dicarbonate; TFA is trifluoroacetic acid; DIPEA is diisopropylethylamine; Pd(dppf)Cl2 is [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II); POCl3 is phosphorus oxychloride; NaH is sodium hydride; LAH is Lithium Aluminium Hydride; Pd(OAc)2 is Palladium (II) acetate; Pd2(dba)3 is tris(dibenzylideneacetone)dipalladium; Pd(PPh3)4 is tetrakis(triphenylphosphine)palladium; Et3SiH is triethylsilane; PPh3 is triphenyl phosphine; Xantphos is 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene; MeSO3H is methanesulfonic acid; Xphos is 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl; Lawesson's reagent is 2,4-Bis(4-methoxylphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide; NBS is N-bromosuccinimide; t-BuOK is potassium tert-butylate;
Compounds are named either manually or by using ChemDraw®, or using vendors catalogue name if commercially available.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 showed the antiproliferative activity of Herceptin and different ADCs and the result suggested that the study ADC001 (EXAMPLE 9) and the control ADC-HA showed comparable activity in the inhibition on the growth of breast cancer cell line HCC1954 in vitro. Herceptin alone is ineffective in this assay.
FIG. 2 showed the tumor growth curves from each group. The result suggested that the study ADC001 (EXAMPLE 9) and the control ADC-HA displayed comparable activity to inhibit tumor growth in the HCC1954 xenograft mice model.
FIGS. 3 and 4 showed the antiproliferative activity of Herceptin and ADCs (ADC002 to ADC006, EXAMPLE 10 to 14) and the result suggested that the study ADCs and the control ADC-HA showed comparable activity in the inhibition on the growth of breast cancer cell line HCC1954 in vitro. Herceptin alone is ineffective in this assay
FIGS. 5 to 10 showed the tumor growth curves for control ADC-HA and ADCs (ADC-002 to ADC006, EXAMPLE 10 to 14).
FIG. 11 showed the comparison of tumor sizes at termination of the study between control ADC-HA and ADCC-002 to ADC006.
FIG. 12 showed the antiproliferative activity of Erbitux, control ADC-EA, ADC007 (EXAMPLE 15) and ADC008 (EXAMPLE 16).
FIG. 13 showed the tumor growth curves for control ADC-EA, ADC007 (EXAMPLE 15) and ADC008 (EXAMPLE 16).
 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
To describe the present invention in more detail, the following examples are provided. However, the scope of the present invention is not limited to these.
INTERMEDIATE 1
Figure US10280229-20190507-C00061
(2S)-2,5-Dioxopyrrolidin-1-yl-2-{[7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoro-heptan-2-yl]amino}-3-methylbutanoate Step 1: (2S)-3-Methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butan-1-ol
Figure US10280229-20190507-C00062
To a stirred suspension of Mg (10.2 g, 420 mmol) with a few small crystals of iodine in 80 mL of THF was added a small portion of a solution of 6-bromohex-1-ene (22.8 g, 140 mmol) in anhydrous THF (40 mL). After the reaction initiated, the remaining 6-bromohex-1-ene THF solution was added dropwise at a rate to maintain a gentle refluxing. After complete addition, the resulting mixture was heated at 70° C. for 1 h. The Grignard reagent (˜120 mL in THF) obtained was then used directly for the next step.
The Grignard reagent from above was cooled to −78° C. and a solution of (4S)-4-isopropyl-2-(trifluoromethyl)oxazolidine (17 g, 93.4 mmol) in THF (40 mL) was added dropwise. The resulting mixture was warmed up to 0° C. and stirred for 1.5 h. The reaction was quenched with sat. NH4Cl (50 mL), extracted with EtOAc (4×100 mL). The organic phase was dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography elution with Pet. ether/EtOAc (0-4%) to give the title compound (11.5 g, 46%) as a yellow oil.
Step 2: (2S)-3-Methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butanoic acid
Figure US10280229-20190507-C00063
To a solution of H5IO6 (33.2 g, 145.8 mmol) in anhydrous CH3CN (100.0 mL) was added CrO3 (486 mg, 4.86 mmol) and stirred at room temperature for 1 h. The mixture was then cooled to 0° C. and a solution of (2S)-3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]-butan-1-ol (6.5 g, 24.3 mmol, in 20 ml CH3CN) was added dropwise. The resulting mixture was stirred at 0° C. for 1.5 h, quenched with K2HPO4 (16.3 g in 50 mL of H2O) and extracted with EtOAc (3×100 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography elution with Pet. ether/EtOAc (0-4%-10% EtOAc) to give the title compound (1.04 g, 12.7%) as a yellow oil.
Step 3: (2S)-Tert-butyl 3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butanoate
Figure US10280229-20190507-C00064
To a solution of (2S)-3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butanoic acid (650 mg, 2.3 mmol) in t-BuOAc (10.0 mL) was added dropwise 70% HClO4 (398 mg, 2.8 mmol) at 0° C. and stirred for 1 h at this temperature. After warming to room temperature and further stirred for 16 h, the reaction mixture was poured into EtOAc (50 mL), washed successively with H2O (30 mL), sat. aq. NaHCO3, (30 ml), and brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash column chromatography elution with Pet. ether/EtOAc (0˜2%˜5%˜10% EtOAc) to give the title compound (0.56 g, 72%) as a colorless oil.
Step 4: (2S)-Tert-butyl 3-methyl-2-[(1,1,1-trifluoro-7-hydroxyheptan-2-yl)amino]butanoate
Figure US10280229-20190507-C00065
To a solution of (2S)-tert-butyl 3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]-butanoate (1.4 g, 4.2 mmol) in anhydrous DCM (6 mL) and MeOH (6 mL) was cooled to −78° C. and charged with O3 for 2 min. The mixture was then warmed to 0° C. and NaBH4 (481 mg, 12.7 mmol) was added. The resulting mixture was stirred at the same temperature for 2 h, quenched with sat. aq NH4Cl (4 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography elution with Pet. ether/EtOAc (4%˜10% EA) to give the title compund 7 (1.05 g, 72%) as a colourless oil.
1H NMR (CDCl3) δ 3.63 (t, J=6.5 Hz, 2H), 3.06 (d, J=6.0 Hz, 1H), 3.01 (d, J=4.6 Hz, 1H), 2.90-2.79 (m, 1H), 1.92-1.80 (m, 1H), 1.67-1.55 (m, 5H), 1.44 (s, 8H), 1.42-1.31 (m, 3H), 0.95-0.83 (m, 6H).
Step 5: (2S)-Tert-butyl 2-((7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoate
Figure US10280229-20190507-C00066
To a solution of triphenyl phosphine (845 mg, 3.2 mmol) in THF (35 mL) at −78° C. under N2 was added DIAD (651 mg, 3.2 mmol) dropwise. The yellow reaction mixture was stirred at −78° C. for 5 min and (2S)-tert-butyl 3-methyl-2-[(1,1,1-trifluoro-7-hydroxyheptan-2-yl)amino]butanoate (1.1 g, 3.22 mmol) in THF (5 mL) was added. After further stirring for 5 min, neopentyl alcohol (142 mg, 1.61 mmol) and 1H-pyrrole-2,5-dione (313 mg, 3.22 mmol) were added to the reaction mixture as solids. The reaction was then stirred overnight at ambient temperature and concentrated. The residue was purified by flash column chromatography elution with Pet. ether/EtOAc (0˜15% EtOAc) to give the title compound (550 mg, 40.7%) as a colorless oil.
1H NMR (CDCl3) δ 6.69 (s, 2 H), 3.52 (t, J=7.2 Hz, 2 H), 3.06-3.01 (m, 1 H), 2.84-2.82 (m, 1 H), 1.89-1.87 (m, 1 H), 1.66-1.52 (m, 8 H), 1.50-1.25 (m, 9 H), 0.95-0.86 (m, 6 H).
Step 6: (2S)-2,5-Dioxopyrrolidin-1-yl-2-{[7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoro-heptan-2-yl]amino}-3-methylbutanoate
Figure US10280229-20190507-C00067
To a solution of (2S)-tert-butyl 2-((7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoate (350 mg, 0.84 mmol) in anhydrous DCM (6 mL) under N2 at 0° C. was added TFA (6 mL) dropwise. The resulting mixture was stirred at room temperature for 2 h, concentrated and co-evaporated with toluene (2×10 mL) to remove TFA. The residue was then re-dissloved in anhydrous THF (5 mL) under N2 at 0° C., and triethylamine (251 mg, 2.492 mmol) was added followed by DCC (171 mg, 0.83 mmol). After stirring at room temperature for 5 min, N-hydroxysuccinimide (96 mg, 0.83 mmol) was added. The mixture was stirred at room temperature for 16 h, filtered and concentrated to give the crude title compound (260 mg), which was used for next reaction step without further purification.
INTERMEDIATE 2 & INTERMEDIATE 3
Figure US10280229-20190507-C00068
(S)-2-(((R)-7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methyl-butanoic acid, (R)-MTMH-Val and (S)-2-(((S)-7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoic acid, (S)-MTMH-Val Step 1: (4S)-4-isopropyl-2-(trifluoromethyl)oxazolidine
Figure US10280229-20190507-C00069
To a mixture of (S)-2-amino-3-methylbutan-1-ol (85 g, 824 mmol, 1.0 eq) and 2, 2, 2-trifluoro-1-methoxy-ethanol (75 g, 577 mmol, 0.7 eq) in toluene (1.5 L) was added PPTS (10.4 g, 41.2 mmol, 0.05 Eq) in one portion at room temperature under N2. The mixture was refluxed for 3 h with azeotropic removal of methanol/water (Dean-Stark trap). TLC showed the reaction was complete. The mixture was cooled to room temperature, filtered and concentrated in vacuum to afford the title compound (86 g, crude) as a yellow oil.
Step 2: (2S)-3-Methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butan-1-ol
Figure US10280229-20190507-C00070
To a mixture of magnesium (18.2 g, 750 mmol, 1.5 eq) and I2 (cat) in THF (500 mL) was added dropwise a solution of 6-bromohex-1-ene (81.5 g, 499.8 mmol, 1.0 eq) in THF (500 mL) at 20° C. over a period of 30 min under N2. During the addition, the reaction temperature risen and was maintained at 60° C. After further stirring at 60° C. for another 1.5 h, the mixture was cooled to room temperature and used for the next step without purification.
To Grignard reagent, bromo(hex-5-enyl) magnesium (0.5 M, 500 mL, 1.25 eq) from above at −78° C. under N2 was added dropwise a solution of (4S)-4-isopropyl-2-(trifluoromethyl)oxazolidine (36.6 g, 200 mmol, 1.00 eq) in THF (300 mL). The mixture was stirred at −78° C. for 30 min, then warmed to 20° C. and stirred for 4.5 h. TLC (PE: EA=5:1) showed the reaction was complete. The mixture was quenched with NH4Cl (500 mL) and extracted with EtOAc (1000 mL×3). The combined organic phases were washed with saturated brine (500 mL×2), dried with anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography (Pet. ether:EtOAc=20:1) to afford the title compound (19 g, 35.5% yield) as a yellow oil.
Step 3: (2S)-3-Methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butanoic acid
Figure US10280229-20190507-C00071
To a mixture of (2S)-3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butan-1-ol (19 g, 71 mmol, 1 eq) in CH3CN (515 mL) was added pentahydroxy(oxo)-iodane (48.6 g, 213.2 mmol, 3 eq), CrO3 (142 mg, 1.4 mmol, 0.02 eq) and water (4 mL) at WC. The mixture was stirred at 0° C. for 4 h. TLC showed the reaction was complete. The mixture was concentrated in vacuum. The residue was purified by silica gel chromatography (Pet. ether:EtOAc=10:1) to afford the title compound (16 g, 80% yield) as a yellow oil.
Step 4: (2S)-Tert-butyl 3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butanoate
Figure US10280229-20190507-C00072
To a mixture of (2S)-3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butanoic acid (7 g, 24.9 mmol, 1 eq) in tert-butyl acetate (200 mL) was added 70% HClO4 (7.5 g, 74.7 mmol, 3 eq) in one portion at 30° C. under N2. The mixture was stirred at 30° C. for 3 h. TLC showed the reaction was complete. The mixture was diluted with EtOAc (400 mL) and washed with water (400 mL). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography (Pet. ether:EtOAc=60:1) to afford the title compound (7 g, 83.4% yield) as yellow oil.
Step 5: (2S)-Tert-butyl 3-methyl-2-[(1,1,1-trifluoro-7-hydroxyheptan-2-yl)amino]butanoate
Figure US10280229-20190507-C00073
Ozone was bubbled into a solution of (2S)-tert-butyl 3-methyl-2-[(1,1,1-trifluorooct-7-en-2-yl)amino]butanoate (14.0 g, 41.5 mmol, 1 eq) in DCM (100 mL) and MeOH (10 mL) at −78° C. for 3 min. After excess O3 was purged by N2, NaBH4 (4.7 g, 124.5 mmol, 3 eq) was added at 0° C. The mixture was stirred at 20° C. for 3 h. TLC showed starting material was consumed completely. After quenched by saturated aqueous NH4Cl (50 mL), the mixture was extracted with EtOAc (200 mL). The organic layer was concentrated to give the crude product. The crude product was purified by silica gel chromatography eluted with (Pet. ether:EtOAc=20:1) to give the title compound (11 g, 77.7% yield) as a yellow oil.
Step 6: (2S)-Tert-butyl 2-((7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoate
Figure US10280229-20190507-C00074
To a solution of PPh3 (4.61 g, 17.57 mmol, 1.50 eq) in THF (40 mL) at −78° C. under N2 was added dropwise DIAD (3.55 g, 17.57 mmol, 1.50 eq). After stirred at −78° C. for 5 min, (2S)-tert-butyl 3-methyl-2-[(1,1,1-trifluoro-7-hydroxyheptan-2-yl)amino]butanoate (4.0 g, 11.7 mmol, 1 eq) in THF (5 mL) was added and stirred for 5 min. Followed 2, 2-dimethylpropan-1-ol (774.6 mg, 8.8 mmol, 0.75 eq) and 1H-pyrrole-2,5-dione (1.7 g, 17.6 mmol, 1.5 eq) were added to the reaction mixture as solids. The reaction was stirred for 3 h at 30° C. TLC showed the starting material was consumed. The mixture was concentrated and purified with silica gel column (Pet. ether:EtOAc=10:1) to give the title compound (4.00 g, 9.51 mmol, 81.17% yield) as a white solid.
Step 7: (S)-2-(((R)-7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methyl-butanoic acid, (R)-MTMH-Val and (S)-2-(((S)-7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoroheptan-2-yl)amino)-3-methylbutanoic acid, (S)-MTMH-Val
Figure US10280229-20190507-C00075
A mixture of (2S)-tert-butyl 2-((7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoro-heptan-2-yl)amino)-3-methylbutanoate (6.0 g, 14.3 mmol, 1 eq) in DCM (40 mL) and TFA (40 mL) was stirred at 30° C. for 12 h. The mixture was then concentrated and purified by prep-HPLC (Instrument: Shimadzu pump LC-20A; Column: SYNERGI 200*50 10 um; Mobile phase: A for H2O (Add 0.75% TFA, v/v) and B for CH3CN; Gradient: B 30-60%; Gradient Time: 30 min; Retention Time: 25-30 min; Flow rate: 80 mL/min) to afford peak 1: INTERMEDIATE 2 (3.20 g, 8.78 mmol, 61.55% yield) as a white solid and peak 2, INTERMEDIATE 3 (1.10 g, 3.02 mmol, 21.16% yield) as a yellow oil.
INTERMEDIATE 2, (R)-MTMH-Val: 1H NMR (CDCl3) δ 6.72 (s, 2H), 3.54 (t, 2H), 3.30 (d, 1H), 3.00 (m, 1H), 2.13 (m, 1H), 1.75-1.25 (m, 8H), 1.03 (d, 3H), 0.98 (d, 3H). LCMS: 365.1 (MO.
INTERMEDIATe 3, (S)-MTMH-Val: 1H NMR (CDCl3) δ 6.72 (s, 2H), 3.54 (t, 2H), 3.33 (d, 2H), 2.97 (m, 1H), 2.02 (m, 1H), 1.75-1.25 (m, 8H), 1.03 (d, 3H), 0.99 (d, 3H). LCMS: 365.1 (MH+).
INTERMEDIATE 4
Figure US10280229-20190507-C00076
Cit-PAB-OH Step 1: Fmoc-Cit
Figure US10280229-20190507-C00077
To a solution of L-citrulline (20.00 g, 114.16 mmol, 1.00 eq) in 10% Na2CO3 (200 mL) was added dropwise a solution of Fmoc-Cl (35.40 g, 136.84 mmol, 1.20 Eq) in dioxane (100 mL) at 0° C. over a period of 5 min under N2. The reaction mixture was warmed to 20° C. for 4 h. TLC showed the starting material was consumed completely. The reaction mixture was added H2O (50 mL). The aqueous phase was separated and adjusted to PH 2˜3 with 2M HCl (50 mL). The mixture was extracted with EtOAc (150 mL×3). The combined organic phases were washed with saturated brine (100 mL×2), dried over anhydrous Na2SO4, filtered and concentrated to give the title compound (40.00 g, 100.65 mmol, 88.17% yield) as a white solid. LCMS(ESI): 398.1 (MH+).
Step 2: Fmoc-Cit-PAB-OH
Figure US10280229-20190507-C00078
To a solution of Fmoc-cit (40.00 g, 100.65 mmol, 1.00 Eq) and 4-aminobenzyl alcohol (14.87 g, 120.78 mmol, 1.2 eq) in DCM (1000 mL) was added dropwise a solution of EEDQ (49.78 g, 201.30 mmol, 2.0 eq) in MeOH (500 mL) at 20° C. over a period of 30 min under N2. The reaction mixture was stirred at 20° C. for 16 h. TLC (MeOH:EtOAc=1:10) showed the starting material was consumed completely. The reaction mixture was concentrated and the residue was washed with tert-butyl methyl ether (200 mL×3), filtered and concentrated to give the crude title compound (45.00 g, 89.54 mmol, 88.96% yield) as a white solid.
Step 3: Cit-PAB-OH
Figure US10280229-20190507-C00079
To a solution of Fmoc-cit-PAB-OH (15.00 g, 29.85 mmol, 1.00 Eq) in DMF (124.5 mL) was added dropwise a solution of piperidine (21.93 g, 257.58 mmol, 8.63 Eq) in DMF (20 mL) at 20° C. over a period of 10 min. The reaction mixture was stirred at 20° C. for 3 h. TLC (DCM:MeOH=5:1) showed the starting material was consumed completely. The reaction was washed with DMF (30 mL×2). The combined organic phases were concentrated to give the residue which was purified by pre-HPLC (formic acid) to give the title compound (7.50 g, 26.76 mmol, 89.63% yield) as a white solid. LCMS(ESI): 218.1 (MH+).
INTERMEDIATE 5
Figure US10280229-20190507-C00080
(S)-2-Amino-N-(4-(hydroxymethyl)phenyl)-5-morpholinopentanamide Step 1: (S)-Methyl 2-(((benzyloxy)carbonyl)amino)-5-morpholino-5-oxopentanoate
Figure US10280229-20190507-C00081
To a solution of Z-Glu-OMe (10 g, 33.87 mmol) in dry DMF (100 mL) was added DIPEA (13.13 g, 101.60 mmol), HATU (15.45 g, 40.64 mmol) and morpholine (4.43 g, 50.8 mmol) and then stirred at 20° C. for 16 h. The mixture was poured into water (200 ml) and EtOAc (500 ml). The organic layer was separated, washed with water (100 mL×2) and brine (100 mL), dried over anhydrous NaSO4 and concentrated to give the title compound (11 g, crude) as an oil. MS: 365 (MH+)
Step 2: (S)-Methyl 2-(((benzyloxy)carbonyl)amino)-5-morpholinopentanoate
Figure US10280229-20190507-C00082
To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)amino)-5-morpholino-5-oxopentanoate (3 g, 8.2 mmol) in dry THF (40 mL) was added a solution of 10M borane methyl sulfide complex in THF (4 mL) at 0° C. and then stirred at 16° C. for 16 h. The mixture was quenched with CH3OH and followed by 1M aqueous HCl (40 mL), stirred at 90° C. for 30 min and evaporated to dryness. The residue was dissolved with water (100 mL), adjusted to pH 10 with aq NaOH and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (50 mL×2), dried over anhydrous NaSO4 and concentrated under reduced pressure. The residue from four parallel reactions were pooled and purified by column chromatography (DCM:MeOH=10:1) to give the title compound (5.5 g, yield 47.7%) as an oil. MS: 351 (MH+)
Step 3: (S)-2-(((Benzyloxy)carbonyl)amino)-5-morpholinopentanoic acid
Figure US10280229-20190507-C00083
To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)amino)-5-morpholinopentanoate (5.5 g, 15.70 mmol) in THF (50 mL) was added LiOH —H2O (1.32 g, 31.39 mmol). Then the mixture was stirred at 0° C. for 2 h and evaporated to dryness to give the crude title compound (5.0 g, crude).
Step 4: (S)-Benzyl (1-((4-(hydroxymethyl)phenyl)amino)-5-morpholino-1-oxopentan-2-yl) carbamate
Figure US10280229-20190507-C00084
To a solution of (S)-2-(((benzyloxy)carbonyl)amino)-5-morpholinopentanoic acid (3.00 g, 8.92 mmol) in dry DMF (200 mL) was added HOBt (1.21 g, 8.92 mmol), EDCl (1.71 g, 8.92 mmol) and 4-aminobenzyl alcohol (1.65 g, 13.38 mmol and then stirred at 0° C. for 6 h. The mixture was poured into water (100 mL) and EtOAc (150 mL. The organic layer was separated, washed with water (50 mL×2), brine (50 mL), dried over anhydrous NaSO4 and concentrated under reduced pressure. The residue was purified by column chromatography (DCM:MeOH=10:1) to afford the title compound (1.2 g, yield 30.47%). MS: 442 (MH+)
Step 5: (S)-2-Amino-N-(4-(hydroxymethyl)phenyl)-5-morpholinopentanamide
Figure US10280229-20190507-C00085
To a solution of (S)-benzyl (1-((4-(hydroxymethyl)phenyl)amino)-5-morpholino-1-oxopentan-2-yl)carbamate (600.00 mg, 1.36 mmol) in MeOH (50 mL) was added Pd/C (200.00 mg) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 25° C. for 0.5 h. The catalyst was filtered off and the filtrate was concentrated to afford the crude title compound (350.00 mg). MS: 308 (MH+)
INTERMEDIATE 6
Figure US10280229-20190507-C00086
tert-Butyl ((trans-4-(2-amino-3-((4-(hydroxymethyl)phenyl)amino)-3-oxopropyl)cyclo hexyl)methyl)carbamate Step 1: Trans-4-(((tert-Butoxycarbonyl)amino)methyl)cyclohexanecarboxylic acid
Figure US10280229-20190507-C00087
To a mixture of trans-4-(aminomethyl)cyclohexanecarboxylic acid (50 g, 318 mmol) and Boc2O (69.4 g, 318 mmol) in H2O (500 mL) was added a solution of NaOH (12.7 g, 318 mmol) in H2O (500 mL) in one portion at 15° C. under N2. The mixture was stirred at 15° C. for 16 h. TLC showed most starting material was consumed. The mixture was adjusted to pH 3 with HOAc (40 mL) and extracted with EtOAc (400 mL×3). The combined organic phases were dried with anhydrous Na2SO4, filtered and concentrated to afford the crude title compound (77 g) as a white solid.
1H NMR (CDCl3) δ 4.62 (m, 1H), 2.98 (m, 2H), 2.25 (m, 1H), 2.04 (d, 2H), 1.83 (d, 2H), 1.438-1.37 (m, 12H), 0.96 (m, 2H).
Step 2: tert-Butyl ((trans-4-(hydroxymethyl)cyclohexyl)methyl)carbamate
Figure US10280229-20190507-C00088
To a mixture of trans-4-(((tert-Butoxycarbonyl)amino)methyl)cyclohexanecarboxylic acid (37.0 g, 143.8 mmol) in THF (1 L) was added LiAlH4 (8.2 g, 215.7 mmol) at 0° C. under N2. The mixture was stirred at 15° C. for 16 h. TLC showed the reaction was completed. The mixture was quenched with water (8.2 mL), followed by 15% aqueous NaOH solution (8.2 mL), water (24.6 mL) and filtered. The filtrate was concentrated and the residue was purified by silica gel chromatography (Pet.ether:EtOAc=2:1) to afford the title compound (19.0 g, 54.3% yield) as a white solid.
1H NMR (CDCl3) δ 4.61 (br s, 1H), 3.45 (d, 2H), 2.98 (t, 2H), 1.81 (m, 4H), 1.44 (m, 11H), 0.95 (m, 4H).
Step 3: tert-Butyl ((trans-4-formylcyclohexyl)methyl)carbamate
Figure US10280229-20190507-C00089
To a mixture of oxalyl chloride (11.9 g, 93.7 mmol) in DCM (375 mL) was added a solution of DMSO (11.0 g, 140.5 mmol) in DCM (675 mL) at −65° C. under N2. The mixture was stirred at −65° C. for 30 min. A solution of tert-butyl ((trans-4-(hydroxymethyl)cyclohexyl)methyl)carbamate (19.00 g, 78.08 mmol) in DCM (150 mL) was then added at −65° C. The mixture was further stirred at −65° C. for another 30 min. TLC showed most starting material was consumed. A solution of Et3N (19.4 g, 191.3 mmol) in DCM (75 mL) was added at −65° C. and stirred for 30 min. The mixture was warmed to 20° C., quenched with sat.NH4Cl solution (150 mL) and extracted with DCM (300 mL×3). The combined organic phases were dried with anhydrous Na2SO4, filtered and concentrated to afford the crude title compound (19 g) as yellow oil.
Step 4: Methyl 2-(((benzyloxy)carbonyl)amino)-3-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexyl)acrylate
Figure US10280229-20190507-C00090
To a mixture of tert-butyl ((trans-4-formylcyclohexyl)methyl)carbamate (19.0 g, 78.7 mmol) and methyl 2-(((benzyloxy)carbonyl)amino)-2-(dimethoxyphosphoryl)acetate (28.7 g, 86.6 mmol) in DCM (600 mL) was added DBU (18.0 g, 118.1 mmol) in one portion at 20° C. under N2. The mixture was stirred at 20° C. for 2 h. TLC showed the reaction was completed. The mixture was washed with saturated NaHCO3 (300 mL×2). The organic layer was concentrated and the residue was purified by silica gel chromatography (Pet. ether:EtOAc=3:1) to afford the title compound (20 g, 56.9% yield) as a colorless oil.
1H NMR (CDCl3) δ 7.35 (m, 5H), 6.45 (d, 1H), 6.08 (br s, 1H), 5.15 (s, 2H), 4.60 (br s, 1H), 3.74 (s, 3H), 2.97 (m, 2H), 2.32 (m, 1H), 1.77 (m, 4H), 1.45 (s, 9H), 1.12 (m, 2H), 0.95 (m, 3H).
Step 5: 2-(((Benzyloxy)carbonyl)amino)-3-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclo-hexyl)acrylic acid
Figure US10280229-20190507-C00091
To a mixture of methyl 2-(((benzyloxy)carbonyl)amino)-3-(trans-4-(((tert-butoxycarbonyl) amino)methyl)cyclohexyl)acrylate (20.0 g, 44.8 mmol) in MeOH (150 mL) was added LiOH.H2O (5.6 g, 134.4 mmol) in H2O (50 mL) at 25° C. under N2. The mixture was stirred at 25° C. for 16 h. TLC showed the reaction was completed. The mixture was adjusted to pH 3 with HOAc and concentrated to remove MeOH. The aqueous phase was extracted with ethyl acetate (50 mL×3). The combined organic phases were dried with anhydrous Na2SO4, filtered and concentrated to afford the crude title compound (18.00 g) as a colorless oil.
Step 6: Benzyl (1-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexyl)-3-((4-(hydroxylmethyl)phenyl)amino)-3-oxoprop-1-en-2-yl)carbamate
Figure US10280229-20190507-C00092
A mixture of 2-(((Benzyloxy)carbonyl)amino)-3-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexyl)acrylic acid (18.0 g, 41.6 mmol), 4-aminobenzy alcohol (7.7 g, 62.4 mmol), HATU (23.7 g, 62.4 mmol) and DIPEA (16.1 g, 124.9 mmol) in DMF (600 mL) was stirred at 25° C. for 16 h under N2. TLC showed the reaction was completed. The mixture was diluted with ethyl acetate (600 mL) and washed with sat.NH4Cl solution (600 mL×3). The organic layer was separated, dried with anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography (Pet. ether:EtOAc=1:1) to afford the title compound (14.00 g, 26.04 mmol, 62.56% yield) as a brown solid. MS: 538 (MH+).
Step 7: tert-Butyl ((trans-4-(2-amino-3-((4-(hydroxymethyl)phenyl)amino)-3-oxopropyl)cyclohexyl)methyl)carbamate
Figure US10280229-20190507-C00093
To a solution of Benzyl (1-(trans-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexyl)-3-((4-(hydroxylmethyl)phenyl)amino)-3-oxoprop-1-en-2-yl)carbamate (7.0 g, 13.0 mmol) in MeOH (100 mL) was added 10% Pd/C (1.0 g) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15psi) at 25° C. for 20 min. TLC showed the starting material was consumed completely. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by prep-HPLC to give the title compound (1.4 g, 26.3% yield) as a white solid. MS: 406 (MH+)
INTERMEDIATE 7
Figure US10280229-20190507-C00094
Cit-ABA-PAB-OH Step 1: 4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)butanoic acid
Figure US10280229-20190507-C00095
To a mixture of 4-aminobutanoic acid (5.0 g, 48.5 mmol, 1 eq) in 10% aqueous Na2CO3 solution (16.5 g, 155.7 mmol, 3.2 eq, 150 mL H2O) was added dropwise a solution of (9H-fluoren-9-yl)methyl carbonochloridate (13.8 g, 53.3 mmol, 1.1 eq) in dioxane (100 mL) at 0° C. over a period of 10 min under N2. The mixture was stirred at 20° C. for 4 h. TLC showed the reaction was completed. The mixture was separated and adjusted to PH 2-3 with 2M HCl and extracted with EtOAc (250 mL×3). The combined organic phases were washed with saturated brine (150 mL×2), dried over anhydrous Na2SO4, filtered and concentrated in vacuum to afford the crude title compound (16 g) as a white solid. LCMS: 326.1 (MH+)
Step 2: (9H-Fluoren-9-yl)methyl (4-((4-(hydroxymethyl)phenyl)amino)-4-oxobutyl)carbamate
Figure US10280229-20190507-C00096
To a solution of 4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)butanoic acid (16.0 g, 49 mmol, 1 eq) in DMF (200 mL) was added then HATU (20.6 g, 54.1 mmol, 1.1 eq) and DIPEA (19.1 g, 147.5 mmol, 3 eq) at 20° C. and stirred for 30 min. Then 4-aminobenzyl alcohol (7.3 g, 59.0 mmol, 1.2 eq) was added in one portion at 20° C. The mixture was stirred at 20° C. for 16 h. TLC showed the reaction was completed. The reaction mixture was concentrated in vacuum. The residue was washed with TBME (300 mL×3), filtered and concentrated to afford the crude title compound (15 g) as a yellow solid. LCMS: 431.2 (MH+)
Step 3: 4-Amino-N-(4-(hydroxymethyl)phenyl)butanamide
Figure US10280229-20190507-C00097
To a solution of (9H-fluoren-9-yl)methyl (4-((4-(hydroxymethyl)phenyl)amino)-4-oxobutyl)-carbamate (5.0 g, 11.6 mmol, 1 eq) in DMF (40 mL) was added piperidine (7.9 g, 92.9 mmol, 8 eq) in one portion at 20° C. Then the mixture was stirred at 20° C. for 3 h. TLC (DCM: MeOH=5:1) showed starting material was consumed completely. The reaction mixture was concentrated to give the crude title compound (5 g) as a yellow solid. LCMS: 209.1 (MH+)
Step 4: Fmoc-Cit-ABA-PAB-OH
Figure US10280229-20190507-C00098
To a solution of 4-amino-N-(4-(hydroxymethyl)phenyl)butanamide (600 mg, 2.9 mmol, 1 eq) and Fmoc-cit (1.3 g, 3.2 mmol, 1.1 eq) in DCM (8 mL) was added slowly a solution of EEDQ (1.4 g, 5.8 mmol, 2 eq) in MeOH (8 mL) at 20° C. The mixture was stirred at 20° C. for 16 h. TLC (DCM:MeOH=5:1) showed the reaction was completed. The reaction mixture was concentrated and the residue was purified by prep-TLC (SiO2, DCM:MeOH=5:1) to give the title compound (440 mg, 26% yield) as a white solid. LCMS: 588.3 (MH+)
Step 5: Cit-ABA-PAB-OH
Figure US10280229-20190507-C00099
To a solution of Fmoc-Cit-ABA-PAB-OH (440 mg, 749 umol, 1 Eq) in DMF (10 mL) was added piperidine (510 mg, 6 mmol, 8 eq) in one portion at 20° C. The mixture was stirred at 20° C. for 3 h. TLC (DCM:MeOH=5:1) showed the reaction was completed. The reaction mixture was concentrated and the residue was purified by prep-TLC (SiO2, DCM:MeOH=5:1) to give the crude title compound (320 mg) as a white solid. LCMS: 366.2 (MH+)
EXAMPLE 1
Figure US10280229-20190507-C00100
MTM H-Val-Cit-PABO(CO)-MMAE Step 1: MTMH-Val-Cit-PAB-OH
Figure US10280229-20190507-C00101
To a solution of crude (2S)-2,5-dioxopyrrolidin-1-yl-2-{[7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,1,1-trifluoro-heptan-2-yl]amino}-3-methylbutanoate (INTERMEDIATE 1) (0.56 mmol) in DMF (5 mL) was added Cit-PAB-OH (INTERMEDIATE 4) (0.56 mmol) under N2. The resulting mixture was stirred at room temperature for 16 h. Solvent was removed in vacuo. The thick oily residue was washed with tert-butyl methyl ether (10 mL×2) to give the crude title compound, which was used for next step without further purification. LCMS(ESI): 627.3 (MH+)
Step 2: MTMH-Val-Cit-PAB (4-nitrophenyl) carbonate
Figure US10280229-20190507-C00102
To a solution of MTMH-Val-Cit-PAB-OH (260 mg crude, 0.56 mmol) in DMF (3 mL) was added bis(4-nitrophenyl) carbonate (340 mg 1.12 mmol) and DIPEA (108 mg, 0.84 mmol). The mixture was stirred at room temperature for about 1 h and concentrated. The residue was washed with tert-butyl methyl ether (10 mL×2) to give the title compound, which was used directly for next step without further purification. LCMS(ESI): 792.3 (MH+)
Step 3: MTMH-Val-Cit-PABO(CO)-MMAE
Figure US10280229-20190507-C00103
To a solution of MMAE (0.28 mmol) and MTMH-Val-Cit-PAB (4-nitrophenyl) carbonate (0.56 mmol) in anhydrous DMF (2.5 mL) was added HOBt (23 mg, 0.17 mmol). After stirring at room temperature for 2 min, pyridine (0.5 mL) was added. The mixture was stirred at room temperature for 16 h and then concentrated. The residue was purified by Prep-HPLC to give the title compound (40 mg, 10.4%) as a white solid, LCMS(ESI):=685.9 [(M/2)H+]
EXAMPLE 2
Figure US10280229-20190507-C00104
(S)-MTMH-Val-Cit-PABO(CO)-MMAE Step 1: (S)-MTMH-Val-Cit-PAB-OH
Figure US10280229-20190507-C00105
To a mixture of (S)-MTMH-Val (INTERMEDIATE 3) (300 mg, 823 umol, 1 eq), HOBt (133.5 mg, 988 umol, 1.20 eq), EDCl (189 mg, 988 umol, 1.20 eq), DIPEA (426 mg, 3.3 mmol, 4 eq) and Cit-PAB-OH (INTERMEDIATE 4) (277 mg, 988 umol, 1.20 eq) in DMF (10 mL) was stirred at 30° C. for 6 h. TLC showed the reaction was completed. The mixture was concentrated in vacuum. The residue was purified by prep-TLC (EtOAc:MeOH=10:1) to afford the title compound (410 mg, 52.3% yield) as a white solid. MS: 627 (MH+)
Step 2: (S)-MTMH-Val-Cit-PAB (4-nitrophenyl) carbonate
Figure US10280229-20190507-C00106
To a mixture of (S)-MTMH-Val-Cit-PAB-OH (250 mg, 399 umol, 1 eq) in DMF (10 mL) was added DIPEA (77 mg, 598 umol, 1.5 eq) and bis(4-nitrophenyl) carbonate (243 mg, 798 umol, 2.0 eq) in one portion at 25° C. under N2. The mixture was stirred at 25° C. for 15 h. LCMS showed the reaction was completed. The mixture was concentrated in vacuum. The residue was purified by prep-TLC (EtOAc) to afford the title compound (185 mg, 58.6% yield) as a white solid. MS: 792 (MH+)
Step 3: (S)-MTMH-Val-Cit-PABO(CO)-MMAE
Figure US10280229-20190507-C00107
To a mixture of MMAE (200 mg, 279 umol, 1 eq) and LS)-MTMH-Val-Cit-PAB (4-nitrophenyl) carbonate (250 mg, 316 umol, 1.13 eq) in DMF (10 mL) was added HOBt (25 mg, 185 umol, 0.66 eq) and pyridine (980 mg, 12.4 mmol, 44.5 eq.) in one portion at 25° C. under N2. And then the reaction mixture was allowed to stir at 25° C. for 15 h. LCMS showed the reaction was completed. The mixture was diluted with EtOAc (200 mL) and washed with water (150 ml×3). The organic layer was concentrated to give the residue which was purified by prep-HPLC (FA) to give the title compound (109 mg, 30% yield) as a white solid. LCMS (ESI): 686 [(M/2)H+]
EXAMPLE 3
Figure US10280229-20190507-C00108
(R)-MTMH-Val-Cit-PABO(CO)-MMAE
The title compound was prepared in a similar manner as described for (S)-MTMH-Val-Cit-PABO(CO)-MMAE (EXAMPLE 2), step 1 to 3, from (R)-MTMH-Val (INTERMEDIATE 2) and Cit-PAB-OH (INTERMEDIATE 4). LCMS (ESI): 686.1 [(M/2)H+]
EXAMPLE 4
Figure US10280229-20190507-C00109
(R)-MTMH-DP1-PABO(CO)-MMAE Step 1: (R)-MTMH-DP1-PAB-OH
Figure US10280229-20190507-C00110
To a solution of (S)-MTMH-Val (INTERMEDIATE 2) (350 mg, 0.96 mmol) in DMF (15 mL) was added HOBt (155.75 mg, 1.15 mmol), EDO (220.97 mg, 1.15 mmol), DIPEA (496.59 mg, 3.84 mmol) and (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-morpholinopentanamide (INTERMEDIATE 5) (390 mg, 1.1 mmol) under N2 and was then stirred at 25° C. for 6 h. The reaction mixture was evaporated to dryness and the residue was purified by column chromatography (EtOAc:MeOH=10:1) to afford the title compound (400 mg, yield 63.70%). MS: 654 (MO
Step 2: (R)-MTMH-DP1-PAB (4-nitrophenyl) carbonate
Figure US10280229-20190507-C00111
To a solution of (R)-MTMH-DP1-PAB-OH in DMF (10 mL) was added DIEA (77.10 mg, 0.597 mmol) and bis(4-nitrophenyl) carbonate (349 mg, 1.15 mmol) under N2. The mixture was stirred at 25° C. for 16 h and evaporated to dryness. The residue was purified by prep-TLC (EtOAc) to afford the title compound (300 mg, yield 79.84%). MS: 819 (MO
Step 3: (R)-MTMH-DP1-PABO(CO)-MMAE
Figure US10280229-20190507-C00112
To a solution of (R)-MTMH-DP1-PAB (4-nitrophenyl) carbonate (200 mg, 0.244 mmol) in DMF (4 mL) was added MMAE (200 mg, 0.278 mmol), HOBt (10 mg, 0.074 mmol) and pyridine (0.8 mL) under N2. The mixture was stirred at 25° C. for 16 h, diluted with EtOAc (50 mL), washed with water (20 mL×2), brine (20 mL) and concentrated. The residue was purified by prep-HPLC (FA) to afford the title compound (160 mg, yield 46.87%). LCMS (ESI): 699.5 [(M/2)H+]
EXAMPLE 5
Figure US10280229-20190507-C00113
(R)-MTMH-DP2-PABO(CO)-MMAE
The title compound was prepared in a similar manner as (R)-MTMH-DP1-PAB(CO)-MMAE (EXAMPLE 4) but with piperidine to replace morpholine of INTERMEDIATE 5 for the required corresponding intermediate. LCMS (ESI): 698.6 [(M/2)H+]
EXAMPLE 6
Figure US10280229-20190507-C00114
(R)-MTMH-DP3-PABO(CO)-MMAE Step 1: (R)-MTMH-Boc-DP3-PAB-OH
Figure US10280229-20190507-C00115
To a mixture of (S)-MTMH-Val (INTERMEDIATE 2) (225.0 mg, 617.5 umol) in DMF (12 mL) was added HOBt (108.5 mg, 802.8 umol), EDO (153.9 mg, 802.8 umol) and DIEA (239.4 mg, 1.9 mmol) at 25° C. under N2. After 5 min, tert-butyl ((trans-4-(2-amino-3-((4-(hydroxymethyl)phenyl)amino)-3-oxopropyl)cyclohexyl)methyl)carbamate (INTERMEDIATE 6) (300.5 mg, 741.0 umol) was added and the mixture was further stirred at 25° C. for 4 h. TLC showed that most of starting material was consumed. The mixture was diluted with EtOAc (20 mL), washed with sat.NH4Cl solution (30 mL×3) and concentrated. The residue was purified by prep-TLC and then SFC to give the title compound (peak 1: 140 mg, 30% yield) as a white solid.
Step 2: (R)-MTMH-Boc-DP3-PABO(CO)-MMAE
Figure US10280229-20190507-C00116
The title compound was prepared in a similar manner as described for (S)-MTMH-Val-Cit-PABO(CO)-MMAE (EXAMPLE 2), step 2 to 3, from (R)-MTMH-Boc-DP3-PAB-OH. LCMS [((M−100)/2)H+]: 698.5
Step 3: (R)-MTMH-DP3-PAB-MMAE
Figure US10280229-20190507-C00117
To a mixture of (R)-MTMH-Boc-DP3-PABO(CO)-MMAE (200.00 mg, 133.70 umol) in CH3CN (4.25 mL) and H2O (0.25 mL) was added TFA (0.5 mL) in one portion at 25° C. The mixture was stirred at 25-29° C. for 16 h. LCMS showed the reaction was complete. The mixture was concentrated under reduced pressure at 40° C. The residue was purified by pre-HPLC (FA), without further concentration and lyophilized directly to afford the title compound (105.00 mg, 56.3% yield) as a white solid. LCMS: 698.7 [(M/2)H+]
EXAMPLE 7
Figure US10280229-20190507-C00118
(S)-MTMH-Val-Cit-PABO(CO)-ABA-MMAE Step 1: (S)-MTMH-Val-Cit-PABO(CO)-ABA
Figure US10280229-20190507-C00119
To a mixture of (S)-MTMH-Val-Cit-PAB (4-nitrophenyl) carbonate (420 mg, 531 umol, 1 eq) and 4-aminobutanoic acid (109 mg, 1.1 mmol, 2 eq) in DMF (8 mL) was added DIPEA (205 mg, 1.6 mmol, 3 eq) in one portion at 20° C. under N2. And then the reaction mixture was allowed to stir at 20° C. for 12 h. TLC (Dichloromethane:Methanol=10:1) showed the reaction was complete. The mixture was diluted with EtOAc (50 mL), washed with water (50 ml) and concentrated under vacuum. The residue was purified by pre-TLC (DCM/MeOH=10:1) to give the title compound (236 mg, 46.47% yield, ˜79% purity) as a white solid. MS: 756.3 (MH+)
Step 2: (S)-MTMH-Val-Cit-PABO(CO)-ABA-MMAE
To a mixture of (S)-MTMH-Val-Cit-PABO(CO)-ABA (50 mg, 66 umol, 1 eq) and DIEA (26 mg, 198 umol, 3 eq) in DMF (3 mL) was added HATU (30 mg, 79 umol, 1.2 eq) in one portion at 10° C. under N2. The mixture was stirred at 10° C. for 30 min, then MMAE (47.5 mg, 66 umol, 1 eq) was added and the mixture was further stirred at 28° C. for 12 h. LCMS showed the reaction was completed. The mixture was concentrated and the residue was purified by pre-HPLC (Column, Phenomenex Synergi C18 150*25*10 um; Condition, 0.225% FA-CAN; Begin B, 45; End B, 75; Gradient Time(min), 10; 100% B Hold Time(min), 2; Flow Rate (ml/min), 25) to give the title compound (25 mg, 26% yield) as a white solid. LCMS: 728.7[(M/2)H+]
EXAMPLE 8
Figure US10280229-20190507-C00120
(S)-MTMH-Val-Cit-ABA-PABO(CO)-MMAE Step 1: (S)-MTMH-Val-Cit-ABA-PAB-OH
Figure US10280229-20190507-C00121
To a solution of (S)-MTMH-Val (INTERMEDIATE 3) (383 mg, 1.05 mmol, 1.2 eq) in DMF (8 mL) was added DIPEA (453 mg, 3.50 mmol, 4 eq), HOBt (142 mg, 1.05 mmol, 1.2 eq) and EDCl (202 mg, 1.05 mmol, 1.2 eq) in one portion at 20° C. and stirred for 10 min under N2 Cit-ABA-PAB-OH (INTERMEDIATE 7) (320 mg, 876 umol, 1 eq) was added in one portion at 20° C. and the mixture was further stirred at 20° C. for 16 h under N2. TLC (DCM:MeOH=5:1) showed the reaction was completed. The reaction mixture was concentrated and the residue was purified by prep-TLC (SiO2, DCM:MeOH=5:1) to give the crude title compound (370 mg). LCMS: 712.2 (MH+)
Step 2: (S)-MTMH-Val-Cit-ABA-PAB (4-nitrophenyl) carbonate
Figure US10280229-20190507-C00122
To a solution of (S)-MTMH-Val-Cit-ABA-PAB-OH (370 mg, 520 umol, 1 eq) in DMF (10 mL) was added DIPEA (80.6 mg, 624 umol, 1.2 eq) at 20° C. was added bis(4-nitrophenyl) carbonate (206 mg, 676 umol, 1.3 eq) in one portion at 20° C. under N2. The mixture was stirred at 20° C. for 16 h. TLC (DCM:MeOH=10:1) showed starting material was consumed completely. The mixture was concentrated and the residue was purified by pre-TLC (SiO2, DCM:MeOH=10:1) to give the title compound (70 mg, 79.83 umol, 15.36% yield) as a yellow oil. LCMS: 877.3 (MH+)
Step 3: (S)-MTMH-Val-Cit-ABA-PABO(CO)-MMAE
Figure US10280229-20190507-C00123
To a solution of (S)-MTMH-Val-Cit-ABA-PAB (4-nitrophenyl) carbonate (70 mg, 80 umol, 1 eq) and MMAE (57.3 mg, 79.8 umol, 1 eq) in DMF (6 mL) was added HOBt (5.4 mg, 39.9 umol, 0.5 eq) and pyridine (63.1 mg, 798 umol, 10 eq) at 20° C. The mixture was stirred at 20° C. for 16 h. TLC (DCM:MeOH=10:1) showed the reaction was completed. The mixture was concentrated in vacuum and the residue was purified by Pre-HPLC (FA condition; Column: Phenomenex Synergi Max-RP 250*80 10u; Condition: 0.225% FA-ACN; Begin B: 40; End B: 70) to afford the title compound (40.8 mg, 48.6% yield) as a white solid. LCMS: 728.5 [(M/2)H+].
EXAMPLE 9
Figure US10280229-20190507-C00124
Herceptin (240 mg) and drug-linker intermediate MTMH-Val-Cit-PAB-OH (11.3 mg), EXAMPLE 1 was coupled according to the general procedure for conjugation of drug-linker intermediate to herceptin to give the title ADC (168 mg, 70%).
Other ADC Examples With Herceptin Were Prepared In A Similar Manner As Example 9
Figure US10280229-20190507-C00125
ADC Examples With Erbitux Were Also Prepared In A Similar Manner As Example 9
Figure US10280229-20190507-C00126
Screening of Suitable Dipeptide Units for Drug-Linker Intermediates
A convenient method was developed to identify suitable dipeptide units for the use in drug-linker intermediates. Cbz-protected dipeptides incorporated a fluorescent tag (7-amino-4-methylcouramin, 7-AMC) via a para-aminobenzyl carbonyl fragment were prepared by standard peptide chemistry as shown in Scheme 1. These dipeptide substrates were then incubated with bovine cathepsin B under a similar condition as described by Dubowchik (Biorg. Med. Chem. Lett. 1998, 8, 3341-3346). Rate of hydrolysis by bovine cathepsin B was measured by the release of 7-AMC (Table 1). Novel dipeptides with hydrolysis rates slower than the substrate A were rejected. The three dipeptide units in FS-9, FS-10 and FS-11 were selected as additional dipeptide units for drug-linker intermediate preparation.
Figure US10280229-20190507-C00127
TABLE 1
Rate of hydrolysis under the incubation with bovine cathepsin B
Rate of Hydrolysis
Fluorescent Substrate (nmmol/min/mg)
Figure US10280229-20190507-C00128
 		2.67
Figure US10280229-20190507-C00129
 		0.84
Figure US10280229-20190507-C00130
 		0.59
Figure US10280229-20190507-C00131
 		0.63
Figure US10280229-20190507-C00132
 		0.84
Figure US10280229-20190507-C00133
 		0
Figure US10280229-20190507-C00134
 		0.55
Figure US10280229-20190507-C00135
 		0
Figure US10280229-20190507-C00136
 		0
Figure US10280229-20190507-C00137
 		27.2
Figure US10280229-20190507-C00138
 		25.1
Figure US10280229-20190507-C00139
 		20.9

In Vitro Cytotoxicity Study
  • (a) Breast Cancer Cell Line HCC1954
Breast cancer cell line HCC1954 was grown in RPM11640 medium supplemented with 10% fetal bovine serum and maintained in an atmosphere of 5% CO2 in a humidified 37° C. incubator.
The day before treatment, cells were collected and seeded into 96-well plates (2,000 cells per well). On the second day, cells were treated with a dilute concentration of Herceptin and ADCs of this invention (1, 0.3333, 0.1111, 0.037, 0.0123, 0.0041, 0.0014, 0.00046 and 0.00015 μg/ml). Each treatment was performed in triplicate.
After 72 hours treatment, cell viability was assessed by Cell Titer-Glo kit (Promega) according to the manufacturer's instruction.
The study was compared to a control ADC (ADC-HA) with the normal amide bond at the carbon center bearing the trifluoromethyl group.
Figure US10280229-20190507-C00140
  • (b) A-431 Cell Line
Epidermoid carcinoma cell line A431 was grown in DMEM medium supplemented with 10% fetal bovine serum and maintained in an atmosphere of 5% CO2 in a humidified 37° C. incubator.
The day before treatment, cells were collected and seeded into 96-well plates (2,000 cells per well). On the second day, cells were treated with a dilute concentration of Erbitux and ADCs of this invention (10, 3.33, 1.11, 0.37, 0.123, 0.041, 0.014, 0.0046 and 0.0015 μg/ml). Each treatment was performed in triplicate.
After 72 hours treatment, cell viability was assessed by Cell Titer-Glo kit (Promega) according to the manufacturer's instruction.
The study was compared to a control ADC (ADC-EA) with the normal amide bond at the carbon center bearing the trifluoromethyl group.
Figure US10280229-20190507-C00141
In Vivo Efficacy Study
  • (a) HCC1954 Xenograft Mice Model
7-8 Week old female NOD-SCID mice were injected with HCC1954 cells subcutaneously. Treatment was started 7 days after cell injection once the mean estimated tumor mass reached 153 mm3. Mice were grouped randomly according to the tumor volume and body weight (8 animals per group). Animals were treated with ADCs of this invention (15 mpk), Herceptin (15 mpk) as well as vehicle control on day 0 and day 15. Animals were euthanized on day 28 after the start of treatment, when the tumor volume of vehicle control group reached a mass of 1092 mm3.
  • (b) A-431 Xenograft Mice Model
6-8 Week old female Balb/c nude mice were injected with A431 cells subcutaneously. Treatment was started 10 days after cell injection once the mean estimated tumor mass reached 172 mm3. Mice were grouped randomly according to the tumor volume and body weight (8 animals per group). Animals were treated with ADCs of this invention (10 mpk), Erbitux (10 mpk) as well as vehicle control on day 0 and day 15. Animals were euthanized on day 25 after the start of treatment, when the tumor volume of vehicle control group reached a mass of 2000 mm3.

Claims (29)

What is claimed is:
1. A linker of formula (I) to connect drugs to antibodies,
Figure US10280229-20190507-C00142
wherein,
R is selected from the group consisting of CF2H, CF3, CF2CF3, and PhSO2Me;
Q is selected from the group consisting of
Figure US10280229-20190507-C00143
L1 is selected from the group consisting of —(CR1R2)m—(CR3R4)—(CR1R2)n—, —(CR1R2)m—(CR3R4)—O—(CR1R2)n—, and —[(CR1R2)(CR1R2)X]p—(CR1R2)q—;
m is 1, 2, 3, or 4;
n is 1, 2, 3, or 4;
p is 1, 2, 3, 4, 5, or 6;
q is 1 or 2;
R1 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
R2 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
R3 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
R4 is selected from the group consisting of H, C1-3 alkyl, OH, NR5R6, CO2H, P(O)(OH)2, and SO3H, said C1-3 alkyl is optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
R5 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
R6 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
X is selected from the group consisting of NR7, O, S(O)r;
r is 0, 1, or 2;
R7 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
L2 is a di-peptide unit selected from
Figure US10280229-20190507-C00144
R8 is selected from the group consisting of methyl, propyl, isopropyl, sec-butyl, benzyl, and
Figure US10280229-20190507-C00145
R9 is selected from the group consisting of (CH2)4NH2, (CH2)3NHCONH2, (CH2)3NHC(═NH)NH2,
Figure US10280229-20190507-C00146
s is 0, 1, 2, 3, or 4;
L3 is a self-immolative unit selected from the group consisting of
Figure US10280229-20190507-C00147
R10 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
each R11 is independently selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2;
two geminal R11 may be optionally joined together to form a 3-6 membered ring with a carbon atom to which they are attached;
two adjacent R11 may be optionally joined together to form a 5-7 membered ring with a carbon atom to which they are attached;
R12 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2; and
R13 is selected from the group consisting of H and C1-3 alkyl optionally substituted with 1, 2 or 3 of substituents independently selected from the group consisting of halogen, OH, NH2, NHMe, and NMe2.
2. A drug-linker conjugate of formula (II),
Figure US10280229-20190507-C00148
wherein,
Q′ is selected from the group consisting of
Figure US10280229-20190507-C00149
M is a drug; and
other variables are as defined in claim 1.
3. An anti-drug conjugate (ADC) of formula (III) containing the linker of claim 1,
Figure US10280229-20190507-C00150
wherein,
Y is an antibody;
a is an integer or decimal selected from 1-8;
M is a drug; and
other variables are as defined in claim 1.
4. The linker of claim 1, wherein the antibody is selected from the group consisting of a resurfaced monoclonal antibody, a resurfaced single chain monoclonal antibody, or a resurfaced monoclonal antibody fragment;
or the antibody is selected from the group consisting of a humanized monoclonal antibody, a humanized single chain monoclonal antibody, or a humanized monoclonal antibody fragment;
or the antibody is selected from the group consisting of a chimeric antibody, a chimeric antibody fragment, a domain antibody, or a domain antibody fragment thereof;
or the antibody is selected from the group consisting of MY9, anti-B4, EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFR, EGFRvIII, HER2, HER3, mesothelin, cripto, alphavbeta3, alphavbeta5, alphavbeta6 integrin or C242;
or the antibody is selected from the group consisting of My9-6, B4, C242, N901, DS6, EphA2 receptor, CD38, IGF-IR, CNTO 95, B-B4, Trastuzumab, Tertuzumab, Bevatuzumab, Sibrotuzumab, Rituximab, and Adalimumab;
or the antibody is selected from the group consisting of Herceptin and Erbitux.
5. The linker of claim 1, wherein the antibody binds to target cells selected from tumor cells; virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing one or more of IGF-IR, CanAg, EGFR, MUCI, MUCI 6, VEGF, TF, MY9, anti-B4, EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD11a, CD18, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD70, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFRvIII, HER2/neu, HER3, mesothelin, cripto, alphavbeta3 integrin, alphavbeta5 integrin, alphavbeta6integrin, Apo2, and C242 antigens; or cells expressing insulin growth factor receptor, epidermal growth factor receptor, and folate receptor.
6. The linker of claim 1, wherein the drug is a cytotoxic drug, or the drug is a diagnostic or detection reagent.
7. The linker of claim 1, wherein L1 is selected from the group consisting of:
Figure US10280229-20190507-C00151
8. The linker of claim 1, wherein L2 is selected from the group consisting of
Figure US10280229-20190507-C00152
9. The linker of claim 1, wherein the ring formed by two geminal R11 or two adjacent R11 is cyclohexyl.
10. The linker of claim 1, wherein L3 is selected from the group consisting of
Figure US10280229-20190507-C00153
11. The linker of claim 1, wherein the moiety of
Figure US10280229-20190507-C00154
is selected from the group consisting of
Figure US10280229-20190507-C00155
12. The linker of claim 1, wherein the linker is selected from the group consisting of
Figure US10280229-20190507-C00156
Figure US10280229-20190507-C00157
13. The drug-linker conjugate of claim 2, it is selected from the group consisting of
Figure US10280229-20190507-C00158
Figure US10280229-20190507-C00159
14. The ADC of claim 3, it is selected from the group consisting of
Figure US10280229-20190507-C00160
Figure US10280229-20190507-C00161
Y is an antibody, a is an integer or decimal selected from 1-8.
15. A pharmaceutical composition comprising an effective amount of the ADC of claim 3 and a pharmaceutically acceptable carrier, diluent or excipient.
16. A process for treating a patient in need of a medicament for cancers, comprising administering to the patient a medicament comprising an effective amount of the linker in claim 1.
17. A process for treating or diagnosising a patient in need of a medicament for cancers, comprising administrating to the patient a medicament comprising an effective amount of the ADC of claim 3.
18. An intermediate compound for the synthesis of the drug-linker conjugate of formula (II) in claim 2, comprising:
Figure US10280229-20190507-C00162
19. The linker of claim 5, wherein the tumor cells are selected from breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, and testicular cancer cells.
20. The linker of claim 6, wherein the drug is selected from the group consisting of maytansinoid, DNA-binding drug and its analog, calicheamicin, doxorubicin and its analog, vinca alkaloid, cryptophycin, dolastatin, auristatin and analog thereof, tubulysin, epothilone, taxoid and siRNA; or the drug is a radio-labeled compound.
21. The linker of claim 20, wherein the DNA-binding drug is CC-1065; or the drug is labeled with 3H, 18F, 11C, 13N, 15O, 201Tl, 32P, 51Cr, 67Ga, 123I, 125I, 131I, 132I, 131Cs, 113Xe, 133Xe, 169Yb,198Au, 203Hg, 99mTc, 113mIn, 133mIn, 75Se, 186Re, 153Sm, and 89Sr.
22. The drug-linker conjugate of claim 6, wherein M is selected from the group consisting of
Figure US10280229-20190507-C00163
23. The linker of claim 8, wherein L2 is selected from the group consisting of
Figure US10280229-20190507-C00164
24. The drug-linker conjugate of claim 2, the moiety of
Figure US10280229-20190507-C00165
is selected from the group consisting of
Figure US10280229-20190507-C00166
25. The linker of claim 12, wherein the linker is selected from the group consisting of
Figure US10280229-20190507-C00167
Figure US10280229-20190507-C00168
Figure US10280229-20190507-C00169
26. The drug-linker conjugate of claim 13, it is selected from the group consisting of
Figure US10280229-20190507-C00170
Figure US10280229-20190507-C00171
Figure US10280229-20190507-C00172
27. The ADC of claim 14, it is selected from the group consisting of
Figure US10280229-20190507-C00173
Figure US10280229-20190507-C00174
Figure US10280229-20190507-C00175
wherein Y is an antibody, a is an integer or decimal selected from 1-8.
28. The ADC of claim 27, it is selected from the group consisting of
Figure US10280229-20190507-C00176
Figure US10280229-20190507-C00177
wherein a is an integer or decimal selected from 2-6.
29. The ADC of claim 28, it is selected from the group consisting of
Figure US10280229-20190507-C00178
Figure US10280229-20190507-C00179
Figure US10280229-20190507-C00180
Figure US10280229-20190507-C00181
wherein a is an integer or decimal selected from 2-6.
US15/326,386 2014-07-16 2015-07-13 Linkers and their application towards ADC Active 2035-08-13 US10280229B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/082292 2014-07-16
PCT/CN2014/082292 WO2016008112A1 (en) 2014-07-16 2014-07-16 Linkers and application towards adc thereof
WOPCT/CN2014/082292 2014-07-16
PCT/CN2015/083840 WO2016008392A1 (en) 2014-07-16 2015-07-13 Linkers and their application towards adc

Publications (2)

Publication Number Publication Date
US20170202974A1 US20170202974A1 (en) 2017-07-20
US10280229B2 true US10280229B2 (en) 2019-05-07

Family

ID=55077810

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/326,386 Active 2035-08-13 US10280229B2 (en) 2014-07-16 2015-07-13 Linkers and their application towards ADC

Country Status (7)

Country Link
US (1) US10280229B2 (en)
EP (1) EP3169368B1 (en)
JP (2) JP6688790B2 (en)
CN (1) CN107427591B (en)
ES (1) ES2867749T3 (en)
TW (1) TWI579000B (en)
WO (2) WO2016008112A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
US10233212B2 (en) 2015-11-03 2019-03-19 Industrial Technology Research Institute Compounds, linker-drugs and ligand-drug conjugates
CN116672463A (en) * 2017-02-17 2023-09-01 浙江特瑞思药业股份有限公司 Preparation method of targeted CD20 antibody coupling drug, antibody coupling drug and application thereof
CN108452319A (en) * 2017-02-20 2018-08-28 浙江特瑞思药业股份有限公司 Target the antibody coupling pharmaceutical preparation of CD20
CN107488231B (en) * 2017-09-15 2020-10-30 四川大学 anti-CD 56 antibodies and uses thereof
CN107744592B (en) * 2017-09-15 2020-04-28 四川大学 anti-CD 56 antibody and dolastatin coupling compound and preparation method and application thereof
WO2019149116A1 (en) * 2018-01-30 2019-08-08 四川科伦博泰生物医药股份有限公司 Method for preparing conjugate
JP2021181405A (en) * 2018-08-29 2021-11-25 Jsr株式会社 Polypeptide purification method
AU2020204250B2 (en) 2019-05-20 2021-04-08 Mabplex International Co., Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
CN111670053B (en) * 2019-05-20 2023-08-22 烟台迈百瑞国际生物医药股份有限公司 One-pot method preparation technology of antibody drug conjugate intermediate
CN113880731A (en) * 2021-10-28 2022-01-04 成都市科隆化学品有限公司 Fmoc-D-Cit optical purity purification method and obtained product

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20060024317A1 (en) 2004-05-19 2006-02-02 Medarex, Inc Chemical linkers and conjugates thereof
US20070082365A1 (en) 1998-12-10 2007-04-12 Adnexus Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2007085930A1 (en) 2006-01-25 2007-08-02 Sanofi-Aventis Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2008103693A2 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
US20090018086A1 (en) 2005-07-07 2009-01-15 Seattle Genetics, Inc. Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus
US20090111756A1 (en) 2005-07-07 2009-04-30 Seattle Genectics, Inc. Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus
WO2009099741A1 (en) 2008-02-01 2009-08-13 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
WO2009141240A1 (en) 2008-05-20 2009-11-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Novel dual targeting antitumoural conjugates
WO2010091150A1 (en) 2009-02-05 2010-08-12 Immunogen, Inc. Novel benzodiazepine derivatives
US20110020343A1 (en) 2008-03-18 2011-01-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2011023883A1 (en) 2009-08-25 2011-03-03 Sanofi-Aventis Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
WO2012112708A1 (en) 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
WO2013163229A1 (en) 2012-04-24 2013-10-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973947A (en) 2004-06-01 2013-03-20 健泰科生物技术公司 Antibody-drug conjugates and methods
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
CN108465112B (en) * 2012-05-15 2022-04-29 西雅图基因公司 Self-stabilizing linker conjugates

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US20070082365A1 (en) 1998-12-10 2007-04-12 Adnexus Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20050009751A1 (en) 2001-04-30 2005-01-13 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20060074008A1 (en) 2002-07-31 2006-04-06 Senter Peter D Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20080226657A1 (en) 2003-11-06 2008-09-18 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20060024317A1 (en) 2004-05-19 2006-02-02 Medarex, Inc Chemical linkers and conjugates thereof
US20090018086A1 (en) 2005-07-07 2009-01-15 Seattle Genetics, Inc. Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus
US20090111756A1 (en) 2005-07-07 2009-04-30 Seattle Genectics, Inc. Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus
WO2007085930A1 (en) 2006-01-25 2007-08-02 Sanofi-Aventis Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2008103693A2 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
JP2010519310A (en) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド Chemical linker having a single amino acid and complex thereof
US20080311134A1 (en) 2007-05-08 2008-12-18 Junutula Jagath R Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2009099741A1 (en) 2008-02-01 2009-08-13 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
US20110020343A1 (en) 2008-03-18 2011-01-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2009141240A1 (en) 2008-05-20 2009-11-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Novel dual targeting antitumoural conjugates
WO2010091150A1 (en) 2009-02-05 2010-08-12 Immunogen, Inc. Novel benzodiazepine derivatives
WO2011023883A1 (en) 2009-08-25 2011-03-03 Sanofi-Aventis Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents
WO2012112708A1 (en) 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
WO2013163229A1 (en) 2012-04-24 2013-10-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Denis C. Roy et al., "Anti-MY9-Blocked-Ricin: An Immunotoxin for Selective Targeting of Acute Myeloid Leukemia Cells", Blood, vol. 77(11), pp. 2404-2412, 1991.
Denis C. Roy et al., "Elimination of Neuroblastoma and Small-Cell Lung Cancer Cells With an Anti-Neural Cell Adhesion Molecule Immunotoxin", Journal of the National Cancer Institute, vol. 88(16), pp. 1136-1145, 1996.
Jul. 12, 2017, EESR issued in European Patent Application No. 15822852.8.
Lee M. Nadler et al., "B4, A Human B Lymphocyte-Associated Antigen Expressed on Normal, Mitogen-Activated, and Malignant B Lymphocytes", The Journal of Immunology, vol. 131(1), pp. 244-250, 1983.
Ravi V. J. et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs", Cancer Reseach, vol. 52, pp. 127-131, 1992.
The First Office Action of Japanese patent application 2017-522709 dated Dec. 4, 2018.

Also Published As

Publication number Publication date
ES2867749T3 (en) 2021-10-20
EP3169368A4 (en) 2017-08-09
JP7042291B2 (en) 2022-03-25
US20170202974A1 (en) 2017-07-20
WO2016008392A1 (en) 2016-01-21
CN107427591B (en) 2020-12-29
TW201605481A (en) 2016-02-16
EP3169368A1 (en) 2017-05-24
CN107427591A (en) 2017-12-01
JP2017531027A (en) 2017-10-19
TWI579000B (en) 2017-04-21
EP3169368B1 (en) 2021-02-17
JP2020079251A (en) 2020-05-28
JP6688790B2 (en) 2020-05-20
WO2016008112A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
US10280229B2 (en) Linkers and their application towards ADC
JP6581630B2 (en) New benzodiazepine derivatives
US10722588B2 (en) Cytotoxic benzodiazepine derivatives
US9150649B2 (en) Potent conjugates and hydrophilic linkers
EP3769787A1 (en) Conjugates of cysteine engineered antibodies
EP2723389A2 (en) Novel maytansinoid derivatives with peptide linker and conjugates thereof
JP2023528412A (en) Anti-BCMA antibody-drug conjugates and methods of use
EP4285937A1 (en) Conjugate and use thereof
CN118647408A (en) Conjugate of antibody-eribulin or derivative thereof, intermediate, preparation method, pharmaceutical composition and application
CN115192732A (en) DNA toxic dimer compound and conjugate thereof
NZ618262B2 (en) Novel maytansinoid derivatives with peptide linker and conjugates thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDSHINE DISCOVERY INC., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, CHUN SING;LI, JIAN;CANG, YONG;AND OTHERS;REEL/FRAME:041114/0015

Effective date: 20170112

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4